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Summary 
Rett syndrome is a severe neurodevelopmental disorder, with an incidence of 
~1/1000 female births, in which most patients carry mutations in the methyl-CpG 
binding protein 2 gene. No cure exists so far. Rett girls are born after a normal 
pregnancy and have an apparently normal development throughout the first 6-18 
months of life. Subsequently, they start to show symptoms including severe 
cognitive impairment, stereotypic hand movements, loss of already learned skills, 
epilepsy, intermittent systemic hypoxia, breathing disturbances and impaired 
mitochondrial function. It has been reported that a subunit of complex III of the 
mitochondrial respiratory chain is among the potentially dysregulated genes, the 
inner mitochondrial membrane is leaking protons, and also brain ATP levels seem to 
be affected. In the present work, it could be clearly shown by FAD/NADH 
autofluorescence imaging that increased oxidative burden appears already after the 
first postnatal week in the hippocampus of Rett mice. Furthermore, it has been 
confirmed that the hippocampal synaptic plasticity and the susceptibility to hypoxia 
are impaired. To evaluate whether free radical scavengers are capable of improving 
neuronal and mitochondrial dysfunction, Trolox – a water soluble vitamin E 
derivative – was applied to acute brain slices in vitro. Also chronic in vivo treatment 
was performed by bidaily intraperitoneal injections of Trolox. In vitro experiments 
verified that Trolox dampens neuronal hyperexcitability, reinstates synaptic 
plasticity, ameliorates cellular redox balance, and improves hypoxia tolerance in 
Mecp2-/y hippocampus. Adverse side effects of Trolox on mitochondrial function and 
seizure susceptibility can be excluded. In contrast, chronic in vivo Trolox-treatment 
did not show any beneficial outcome on body weight and/or size, motor function 
and learning, exploratory behavior, breathing function, mitochondria, or neuronal 
network function. The blood glucose level, the hypoxia tolerance as well as the 
short-term potentiation were significantly improved in Mecp2-/y mice by low dose 
Trolox treatment. Taken together, these findings demonstrate that the scavenger 
treatment in vitro is very promising for the treatment of various aspects of the 
neuronal dysfunction in Rett syndrome. However, the in vivo study identifies the 
 
XI  
route of drug administration and frequent animal handling as critical issues to be 





1.1. Classic Rett syndrome 
Rett Syndrome, first described by the Austrian pediatrician Andreas Rett in 1966, is 
classified as a progressive neurodevelopmental disorder (International Statistical 
Classification of Diseases and Related Health Problems (ICD): F84.2). It affects almost 
exclusively girls and is estimated to occur with an incidence of ~1/10.000 live female 
births among all racial and ethnic groups worldwide (Hagberg, 1985; Leonard et al., 
1997). 
 
The disease progression of classic Rett syndrome, including the age of onset and 
especially the severity of symptoms, varies from girl to girl. Rett syndrome is 
characterized by an initial normal development and growth followed by a gradual 
appearance of mental and physical symptoms. As the syndrome progresses, the 
child loses the purposeful use of the hands and the ability to speak. Early symptoms 
mainly include problems with crawling or walking and diminished eye contact. The 
loss of functional use of the hands is followed by distinctive and compulsive hand 
movements such as wringing and washing. Symptoms include severe cognitive and 
mental disabilities – Rett girls often show autism-like behaviors -, slowed growth and 
seizures. Yet, other pronounced symptoms are cardiac abnormalities and very 
pronounced breathing difficulties, while awake, such as hyperventilation, long-
lasting apneas and air swallowing (Shahbazian and Zoghbi, 2001). 
 
Four stages of Rett syndrome have been characterized as described in detail below 
(Weaving et al., 2005). 
 
Stage I, the early onset, typically starts between 6 and 18 months of age. Slowing 
down of the child’s development may not necessarily be noticed. The child begins to 
show less eye contact and has reduced interest in the environment. Hand-wringing 






Stage II, the rapid destructive stage, usually begins between ages 1 and 4 and can 
last for weeks or months. Its onset can be rapid or gradual as the child loses 
purposeful hand skills and the language. Characteristic hand movements such as 
wringing, washing and clapping, as well as repetitive movements of the hands to the 
mouth often start during this stage. Breathing irregularities such as episodes of 
apnea and hyperventilation start to occur. Some girls also display autistic-like 
symptoms such as loss of social interaction and communication. Walking and 
initiating motor movements can be difficult. Slowed head growth is usually noticed 
during this stage.  
 
Stage III, the plateau or pseudo-stationary stage, usually begins between ages 2 and 
10 and can last for years. Apraxia, motor problems, and seizures are pronounced 
during this stage. Many girls remain in this stage for most of their lives.  
 
Stage IV, the late motor deterioration stage, can last for years or even decades. 
Prominent features include reduced mobility, scoliosis, rigidity, spasticity, and 
increased muscle tone. Repetitive hand movements may decrease and eye gaze 
usually improves.  
 
So far, there is no cure for Rett syndrome. Currently available treatments of the 
disorder are only symptomatic and supportive. Constant medication is needed to 
control breathing disturbances, motor difficulties, and anticonvulsant drugs should 
be administered to suppress seizures. Physical therapy can prolong mobility and 
some girls may need nutritional programs to help them maintain an adequate 
weight. 
 
1.2. Genetic background - MECP2 mutations in classic Rett syndrome 
Since physicians can clinically diagnose Rett syndrome only by observing signs and 
symptoms and evaluating the child's physical and neurological status, a genetic test 
has been developed to complement the clinical diagnosis. This involves screening for 
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mutations in the human methyl CpG (cytosine-phosphate-guanine) binding 2 protein 
encoding gene (MECP2) (Buyse et al., 2000). 
 
Mutations in exons 3-4 of the MECP2 coding region have been found in 95% of 
classic Rett patients (Ravn et al., 2005). The MECP2 gene resides on the  
X chromosome and codes for the human methyl-CpG-binding protein 2 (MECP2), 
which was shown to bind selectively to symmetrical 5`-methylated cystones within a 
single CpG dinucleotide (Lewis et al., 1992).  
 
In 70%-90% of sporadic cases and approximately 50% of familial cases, it has been 
shown that mutations in the MECP2 gene are the primary cause of Rett syndrome 
(Shahbazian and Zoghbi, 2001). Almost 70% of reported mutations result from C→T 
transition de novo mutations at one of the eight different 5`-CG.3`(CpG) hotspots 
within the MECP2 gene (Lee et al., 2001). These include four missense and four 
nonsense mutations. Missense mutations have been reported to lead to milder 
forms of Rett syndrome compared to nonsense mutations which cause more severe 
phenotypes (Wan et al., 1999). 
 
Due to the random chromosome X-inactivation pattern, girls with Rett syndrome 
exhibit on the tissue level a mosaic of “healthy” cells with normal MECP2 activity 
and “diseased” cells without MECP2 activity. In classic Rett syndrome, the X-
inactivation pattern is close to 50:50 (Weaving et al., 2003). Yet, skewed X-
inactivation has been implicated in easing the severity of specific X-linked mental 
retardation disorders due to preferred inactivation of the X chromosome that 
contains the mutant allele (Plenge et al., 2002). This explains the high variability in 
the phenotypes of Rett girls. 
 
1.2.1. MeCP2 protein – Function and Expression 
The human MECP2 gene and the mouse ortholog Mecp2 reside on the  
X chromosome (Xq28) and are composed of four exons (Quaderi et al., 1994). The 





methylated DNA and to interact with a high specificity and affinity to symmetrically 
methylated CpG dinucleotides (Lewis et al., 1992). CpG dinucleotides are most 
prominent in the heterochromatic regions of chromosomes as well as in the 
promoter regions of many genes. The mechanism of methylation of cytosine 
residues of CpG dinucleotides is important to guarantee gene silencing. The 
epigenetic mechanism of transcriptional repression has a high importance in X- 
inactivation and imprinting (Jeppesen and Turner, 1993; Pedone et al., 1999).  
 
MeCP2 is a protein that couples deoxyribonucleic acid methylation to the silencing 
machinery. In mice and humans, alternative splicing of the Mecp2/MECP2 gene, 
produces two different isoforms of the protein, MeCPE1 and MeCPE2 that bind 
symmetrically methylated CpG dinucleotides (Meehan et al., 1989; Lewis et al., 
1992). Both MeCP2 isoforms are very similar and share the same functional domains 
(Zachariah and Rastegar, 2012). Yet, the MeCP2E1 is considered to be the major 
isoform in the brain (Dragich et al., 2007).  
 
The human MECP2 polypeptide consists of a methyl-CpG-binding domain (MBD), a 
transcriptional repression domain (TRD) and the nuclear localization signal (NLS). 
The MBD consists of 85 amino acids and resides at the N-terminal end of the 




Figure 1: Schematic representation of the human methyl-CpG-binding protein  
The human MECP2 includes a MBD, the TRD, and the NLS. S80 and S421 indicate potential 
serine phosphorylation sites (modified according to Guy et al., 2011). 
 
Nan and colleagues have shown that MeCP2 represses transcription via binding to 
the methylated CpG dinucleotides and a following recruitment of the co-repressor 
Sin3A and histone deacetylase (HDAC) (Fig. 2) (Nan et al. 1998). Yet, also a 
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correlation between MeCP2 and RNA polymerase II binding sites, which suggests 
that MeCP2 often binds to transcriptionally active promoters, has been shown (Fig. 
2). Chahrour and colleagues have suggested that MeCP2 can function as a 
transcriptional activator. Thus, it appears that MeCP2 may be more correctly 
referred to as a transcriptional modulator rather than a transcriptional repressor 
(Chahrour et al., 2008). In addition to transcriptional regulation, MeCP2 has also 
been confirmed to be involved in alternative splicing (Meehan et al., 1992).  
 
 
Figure 2: MeCP2 and its role in the regulation of transcription 
Transcription is suppressed in promoter regions containing methylated CpGs that are bound 
by MeCP2 protein. MeCP2 binds methylated DNA and recruits chromatin-remodeling 
complexes that contain SIN3A (a transcriptional co-repressor), BRM (a SWI/SNF-related 
chromatin-remodeling protein) and histone deacetylases (HDACs). This leads to chromatin 
condensation owing to histone deacetylation, which results in a limited accessibility of the 
transcriptional machinery to promoter regions. When MeCP2 is not bound to methylated 
DNA (right panel), the complex that usually contains MeCP2, BRM, SIN3A and HDACs is not 
recruited. This lack of MeCP2 binding to DNA could be due to the activity of CDKL5 (cyclin-
dependent kinase-like 5), which is thought to bind and contribute to the phosphorylation of 
MeCP2, resulting in the inability of MeCP2 to bind its methylated binding site (modified 
according to Bienvenu and Chelly, 2006). 
 
According to the brain-specific phenotype associated with MECP2 dysfunction, 
MeCP2 is believed to regulate genes involved in neuronal maturation and in 
maintaining synaptic plasticity. Several neuronal-related genes have been observed 





al., 2007; Chahrour et al., 2008). Therefore, it is interesting, that the brain derived 
neurotrophic factor (Bdnf), which has been shown to be a direct target of MeCP2, 
plays a major role in neuronal development and plasticity as well as the phenotypic 
overlap between mice lacking Bdnf or Mecp2 (Chen et al., 2003; Chang et al., 2006). 
The highest expression of MeCP2 is in the brain, rather in neurons than in glia, and it 
increases progressively during human postnatal brain development (Balmer et al., 
2003). As confirmed by immunohistochemical staining, the onset of increased 
MeCP2 expression is correlated with the state of maturation of different brain 
regions and cell types. This led to the suggestion that MeCP2 may play an important 
role in neuronal maturation (Smrt et al., 2007; Shahbazian et al., 2002; Balmer et al., 
2003). These findings are consistent with the well known features of Rett syndrome 
such as an apparently normal early development and a reduced brain size with 
decreased dendritic branching complexity (Shahbazian et al., 2002). However, 
findings, that in the Mecp2-/y mice the late-onset neurological defects seem to be 
reversible by reexpression of MeCP2, revealed that MeCP2 plays also a role in the 
maintenance of neuronal function (Guy et al., 2007). 
 
1.2.2. MECP2 mutations in males 
Male patients with mild MECP2 mutations are able to survive the neonatal period 
but develop severe mental retardation as well as motor abnormalities (Hoffbuhr et 
al., 2001).  
 
According to Ramocki and coworkers, they can be categorized into four main groups. 
In the first group, males with an extra X chromosome, known as Klinefelter 
syndrome (47, XXY) or somatic mosaicism, harboring a classic Rett syndrome 
mutation, phenotypically show classic Rett syndrome. The second group includes 
karyotypically normal males (46, XY) with MECP2 mutations that cause classic Rett 
syndrome in females; these males show a severe congenital encephalopathy with 
early death. In the third group, males with MECP2 mutations that have not been 
identified in females with Rett syndrome show a variable phenotype of mental 
retardation with spasticity and other features. The fourth group of male patients has 
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been reported to show an increased dosage of the MECP2 gene due to duplication, 
the so-called MECP2 duplication syndrome. These patients are characterized by 
almost the same symptoms like in classic Rett syndrome. Most males suffer from 
moderate to severe intellectual disability, have weak muscle tone in infancy, feeding 
difficulties, poor or absent speech, seizures, and/or spasticity. They have a delayed 
development of motor skills such as sitting and walking. Some lose their previously 
acquired skills (Ramocki et al., 2010). 
 
1.3. Mouse model of Rett syndrome 
In this study, Mecp2tm-1-1Bird mice, lacking exons 3 and 4 of the Mecp2 gene were 
used; indicated as Mecp2-/y or male Rett mice (Fig. 3). These mice are bred on a 
C57/BL6 background and were generated originally using Cre-loxP technology (Guy 
et al., 2001). Male Rett mice with a null mutation show hindlimb-clasping, irregular 
breathing, decreased mobility, stunted body and head growth, microcephaly, and 
death within 6-10 weeks. Neuronal cell bodies and nuclei are reduced in the 
hippocampus, cortex and cerebellum (Chen et al., 2001; Guy et al., 2001). As shown 
by our group, mitochondria and cellular redox balance seem also to be impaired 
(Großer et al., 2012). In addition to this Mecp2 knockout mouse, a variety of other 
Rett mouse models exists, most of which show markedly milder phenotypes 
(Shahbazian et al., 2002; Katz et al., 2009; Wegener et al., 2014). 
 
Even though heterozygous female Rett mice (Mecp2+/–) initially show no symptoms, 
they develop a variable onset of symptoms later in life. Typically, they develop hind-











Figure 3: Mecp2-/y mouse model of Rett syndrome 
Mecp2-/y mice are not distinguishable from their WT littermates until postnatal day (P) ~20. 
During adolescence Mecp2-/y develop symptoms such as reduced body weight- and size, 
motor problems like hind-limb clasping, and highly irregular respiration. 
 
1.4. Mitochondrial dysfunction, oxidative stress and its modulation of 
cellular physiology in Rett syndrome 
Oxidative stress and abnormal mitochondrial metabolism seem to have a common 
origin in neurodegenerative and neurodevelopmental disorders associated with 
mental retardation and intellectual disability. There are strong indications that free 
radicals play a role in cerebral ischemia-reperfusion injury, Parkinson’s disease, 
Alzheimer’s disease, amyotrophic lateral sclerosis, Down syndrome, fragile X 
syndrome, autism and Rett syndrome (Valenti et al.,2014; Zweier et al., 1987; Uttara 
et al., 2009; Gandhi and Abramov, 2012; Perluigi and Butterfield, 2012). In particular, 
the central nervous system is highly vulnerable to free radical damage, due to the 
brain’s high oxygen consumption rate. The fundamental hypothesis of a disturbed 
redox balance is that cumulative oxidative damage over time may contribute to the 







1.4.1. Mitochondrial modulation of cellular processes 
Mitochondria are the main source of the energy required for the maintenance and 
restoration of ion gradients (Duchen, 2000). Presynaptic terminals typically contain a 
couple of mitochondria. Neuronal stimulation of mature hippocampal neurons leads 
to a rapid mitochondrial accumulation in the proximity of dendritic spines (Li et al., 
2004) and causes redistribution and enhancement of their activity in synapses 
(Miller and Sheetz, 2004). Hence, mitochondria-mediated changes in dendritic spine 
densities, shape and formation are suspected to be involved in neuronal and 
synaptic dysfunction and to contribute to neurological disorders (Yuste and 
Bonhoeffer, 2001).  
 
Also neurotransmitters and neurotrophic factors control mitochondrial properties by 
influencing neuronal energy metabolism and dendritic and axonal motility (Liu and 
Shio, 2008; Mattson et al., 2008). Additionally, energy provided by mitochondria is 
essential for transmitting stimuli and signals and therefore crucial for neurogenesis 
and functioning of brain cells and neuronal networks (Valenti et al., 2014). 
 
Disturbed function of the respiratory chain complexes can trigger increased reactive 
oxygen species (ROS) production, leading to oxidative stress (Raha and Robinson, 
2000). Moreover, oxidative stress can be generated by an imbalance between ROS 
production and their scavenging by the cellular antioxidant system consisting of 
antioxidant enzymes such as superoxide dismutase, glutathione peroxidase and 
catalase, and radical scavenging compounds, such as the vitamins C and E (Gandhi 
and Abramov, 2012). 
 
1.4.2. Mitochondrial, synaptic and respiratory dysfunction in Rett 
syndrome 
Mitochondrial dysfunctions, alterations in ROS homeostasis and redox regulation 
appear to be involved in Rett syndrome pathogenesis (Müller and Can, 2014). 
Muscle and frontal lobe biopsies of Rett patients revealed swollen mitochondria 





al., 1990; Dotti et al., 1993). Changes of mitochondrial structure have also been 
confirmed for cortical and hippocampal mitochondria of Mecp2-/y mice (Belichenko 
et al., 2009). Also a decrease in succinate-cytochrome c reductase and cytochrome c 
oxidase activity of muscle and frontal cortex biopsies of Rett patients have been 
shown (Heilstedt et al., 2002; Gibson et al., 2010). Indeed, subunits of complexes I 
and III of the respiratory chain seem to be indirectly controlled by MeCP2 
(Kriaucionis et al., 2006).  
 
More evidence for oxidative burden in Rett syndrome has also been found in 
hippocampal slices of Mecp2-/y mice (Großer et al., 2012). Oxidative stress markers 
such as lipid peroxidation as well as redox imbalance have been reported to be 
increased in blood samples of Rett patients (Sierra et al., 2001; De Felice et al., 2011; 
De Felice et al., 2012). Since mitochondria are a major source of superoxide and 
because ROS output is directly linked to mitochondrial activity (Boveris and Chance, 
1973) an increased basal mitochondrial respiration may lead to intensified ROS 
formation and consequently an imbalance in cellular redox status. In fact, blood 
samples of Rett patients revealed a reduced activity of the scavenging enzyme 
superoxide dismutase (Sierra et al., 2001) as well as decreased vitamin E levels 
(Formichi et al., 1998). Moreover, a recent study showed that brain redox changes 
could be detected already prior to symptoms onset (De Felice et al., 2014). 
 
Long-term potentiation (LTP) is a form of synaptic plasticity, which is considered to 
underlie long-term memory formation. Impairments in LTP induction and/or 
maintenance have been correlated with general learning and memory deficits and 
alterations in synaptic plasticity. Electrophysiological studies of mouse models of 
Rett syndrome revealed impairments in long-term synaptic plasticity (Chen et al., 
2001; Guy et al., 2001; Shahbazian et al., 2002; Pelka et al., 2006). Reduced LTP 
could be observed in hippocampal slices of Mecp2-/y mice (Asaka et al., 2006). Also 
cortical slices of Mecp2308/y mice, a mouse line expressing a truncated MeCP2 
protein, showed diminished LTP induction suggesting that deficits in synaptic 
plasticity result from MeCP2 dysfunction (Moretti et al., 2006). Interestingly, even 
paired pulse facilitation (PPF), a well known test of short-term plasticity, is already 
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impaired in MeCP2 loss of function mutants (Asaka et al., 2006; Moretti et al., 2006; 
Fischer et al., 2009). In line with these findings, it has been also demonstrated that 
MeCP2 plays a fundamental role in synaptic homeostasis (Blackman et al., 2012). 
 
It is known that the sudden death in Rett patients may arise as a consequence of 
cardiac dysfunction and breathing disturbances. In particular, the awake state is 
characterized by phases of irregular breathing and each of which goes along with a 
drop in the arterial O2 level (< 60 mmHg) (Julu et al., 2001). This repeated hypoxia 
may lead to major changes of structure, function, and dynamics of mitochondria and 
because Rett patients run through several intermittent hypoxic episodes, this may 
aggravate the condition of already disturbed mitochondria. 
 
1.5. Pharmacological tools to ameliorate oxidative burden 
In neurodegenerative diseases most studies that focused on antioxidant therapies, 
have been done by administration of vitamin E, vitamin C, and coenzyme Q10. 
Vitamin E was shown for example to reduce amyloid ß deposition and to improve 
cognition in an Alzheimer’s disease mouse model (Conte et al., 2004). In another 
Alzheimer’s disease mouse study, the administration of vitamin C was found to 
dissolve toxic protein aggregates (Cheng et al., 2011). Additionally, the 
administration of coenzyme Q10, has been shown to protect MPTP-treated mice, a 
mouse model for parkinsonism, from dopaminergic neuronal loss and also 
attenuated α-synuclein aggregation (Shults et al., 1999). However, a benefit for the 
use of vitamin E and/or vitamin C in either Alzheimer’s disease or Parkinson’s 
disease from large randomized controlled trials could not be verified so far. 
 
At present, there are no effective treatments to improve cognitive function, 
although numerous researchers aim to find new therapeutic treatments for various 
neurodevelopmental disorders. The strong evidence on the involvement of 
mitochondrial dysfunction and the resulting oxidative stress in the pathogenesis of 
Rett syndrome, leads to the conclusion that improvement of mitochondrial function 





In neurodevelopmental disorders such as fragile X syndrome, Down syndrome and 
Rett syndrome, studies regarding a diet rich of antioxidants, have been already 
intensively tested. Pathophysiological hallmarks such as free radical overproduction, 
oxidative stress and also behavior and learning deficits in a fragile X syndrome 
mouse model, were reversed by the pharmacological treatment with α-tocopherol, 
an antioxidant/radical scavenger (Osakada et al., 2003; de Diego-Otero et al., 2009). 
In case of Down syndrome, coenzyme Q10, acetyl-l-carnitine, α-lipoic acid, α-
tocopherol, and ascorbic acid, all strategies that support mitochondrial functions 
and reduce oxidative stress, have been intensely investigated for treatment of this 
disease (Lott et al., 2011; Pagano and Castello, 2012). Unfortunately, in clinical trials, 
the administration of standard antioxidant supplements has generally failed to 
produce satisfactory therapeutic effects (Lott et al., 2011; Lott et al., 2012).  
 
In contrast, in Rett syndrome, the modulation of oxidative stress seems to be a 
promising approach in the potential therapeutic strategy to reverse some of the 
typical Rett symptoms. The administration of ω-3 polyunsaturated fatty acids 
(PFUAs) has been shown to significantly reduce the levels of several oxidative stress 
biomarkers in the blood of Rett patients. Moreover, a significant reduction in the 
clinical severity of symptoms such as motor-related signs, nonverbal communication 
deficits, and breathing abnormalities, has been observed (De Felice et al., 2012; 
Maffei et al., 2014). 
 
1.6. Challenge to develop new therapies in Rett syndrome 
Even though there is a strong indication of mitochondrial dysfunction in Rett 
syndrome, the detailed cause and origin of defective mitochondria remain still 
unclear. In particular, this includes the question how a loss of function of MeCP2 
could be molecularly connected to a modification of mitochondrial function. Hence, 
further investigations need to be done to discover how alterations in the 
mitochondrial energy metabolism are involved in the pathogenesis of Rett 
syndrome. Furthermore, the very cause and consequences of oxidative stress in Rett 
syndrome need to be clarified.  
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Indeed, preclinical and clinical evidence supports the idea that pharmaceutical 
strategies aimed at improving mitochondrial function and reducing oxidative stress, 
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2. Aim of this Thesis 
1) First of all, the present thesis aimed to clarify if mitochondrial metabolism 
changes occur already at early postnatal stages and may be therefore a potential 
primary cause for the disease progression in Rett syndrome. 
 
2) Vitamin E levels have been shown to be decreased in the blood serum of Rett 
patients (Formichi et al., 1998), therefore supplementation with vitamin E and/or its 
derivatives might be a potential pharmacotherapeutical approach. Hence, the next 
major task was to address, in detail, the potential merit of Trolox in acute 
hippocampal tissue slices of adult Mecp2-/y mice and WT. The main focus was on a 
potential improvement of synaptic function and plasticity, hypoxia tolerance, and 
mitochondrial function in the isolated hippocampal tissue of already symptomatic 
animals. 
 
3) The concluding section of this thesis represents a preclinical trial. In detail, it was 
investigated whether in vivo treatment (intraperitoneal injections) would confirm 
the in vitro results regarding synaptic function and plasticity, hypoxia tolerance, and 
mitochondrial function. Moreover, potential changes in systemic parameters, 
behavioral and motor function after chronic radical scavenger injections were 
evaluated to get a full picture of the treatment efficacy of Trolox. 
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3. Materials and Methods 
All experimental procedures were performed in accordance with the local 
regulations and were approved for the in vitro experiments, “Anoxia und neuronale 
Netzwerke (AZ: T13-08)”, by the office for animal welfare of the Universitätsmedizin 
Göttingen. The in vivo experiments, „Behandlung eines Mausmodells für das Rett 
Syndrom mit Radikalfängern (AZ: 33.9-42502-04-12/0944)“, were authorized by the 
Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit. 
 
3.1. Solutions and pharmacological compounds 
For the experimental procedures all chemicals were obtained from Sigma-Aldrich 
Chemie GmbH, unless stated otherwise.  
 
During the preparation of acute slices and during the electrophysiological and 
optical recordings artificial cerebrospinal fluid (ACSF) was used as the bath solution. 
ACSF was composed of (in mM): 130 NaCl, 3.5 KCl, 1.25 NaH2PO4, 24 NaHCO3, 1.2 
CaCl2, 1.2 MgSO4, and 10 glucose. ACSF was constantly aerated with carbogen, a  
95%O2 and 5% CO2 mixture to adjust the pH to 7.4 and to ensure proper tissue 
oxygenation. The composition of ACSF was based on the cerebrospinal fluid. 
 
To inhibit the enzyme cytochrome c oxidase in the fourth complex of the electron 
transport chain, cyanide (CN-, sodium salt) was dissolved as an aqueous 1 M stock 
solution and stored at -20°C. FCCP (carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone, Tocris Bioscience) was used as an uncoupling agent that dissipates 
the proton gradient across the inner mitochondrial membrane thereby causing 
maximal mitochondrial depolarization. This compound was dissolved in dimethyl 
sulfoxide (DMSO) as 10 mM stock and stored at 4°C. Rhodamine 123 (Rh123), used 
as a measure of mitochondrial membrane polarization, was also dissolved as 10 mM 
stock, and stored at 4°C. All final DMSO concentrations were ≤ 0.02%. To evoke 
seizure-like events (SLEs) the convulsant 4-aminopyridine (4-AP) was dissolved as an 
aqueous 100 mM solution. 




The water-soluble vitamin E derivative Trolox ((+/-)-6-hydroxy-2,5,7,8- 
tetramethylchromane-2-carboxylic acid) (Fig. 4) was directly added to the ACSF in 
the desired final concentration of 1 mM. All working dilutions were prepared 
immediately before use. The injection solution of Trolox was dissolved in phosphate 
buffered saline (PBS) and was prepared on a weekly basis. 
 
 
Figure 4: Chemical structure of Trolox 
Trolox is a water-soluble analog of vitamin E and is used to reduce oxidative stress or 
damage. 
 
3.2. Mouse model of Rett syndrome 
Mice, lacking the MECP2 gene (B6.129P2(C)-Mecp2tm-1-1Bird), were used as a Rett 
mouse model (Guy et al., 2001). Heterozygous female mice were obtained from 
Jackson Laboratories, Bar Harbor, ME. Mice were bred in the central animal facility 
of the University of Göttingen with C57BL/6J wild type (WT) males to generate 
heterozygous females (Mecp2+/-), hemizygous males (Mecp2-/y) and WT mice of 
either gender. Electrophysiological and optical recordings were performed on acute 
tissue slices obtained from hemizygous juvenile male mice between P7-10 or adult 
males ~P46. For all behavioral tests, mice were used around P45 ± 3. Animals were 
kept at a 12 h light-dark cycle and had free access to food pellets and water ad 
libitum. The genotyping of newborn mice was performed by technicians on tail 
biopsy material by using polymerase chain reaction. All Trolox-treated mice were 
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3.3. Systemic Trolox treatment – Drug application 
Starting on P10-11, Mecp2-/y as well as WT mice were treated with Trolox, at 
concentrations of 10 and 40 mg/kg bodyweight, or PBS by performing 
intraperitoneal injections (i.p) every 48 h. Mice were therefore weighted and 
injected according to their body weight. The injection volume was limited to the 
allowed maximum for mice of 10 µl/g. The entire treatment (Fig. 5), the subsequent 
experiments and the analyses were performed as a blinded study. 
 
 
Figure 5: Schematic overview of the Trolox in vivo application 
Mice were injected every 48 h for ~40 days. This was followed by behavioral tests like 
rotarod and open field. The breathing pattern was measured directly before the isolation of 
the brain and final experiments were performed. 
 
3.4. Motor function & behavior 
It is known that in general, Mecp2 knockout mice display a noticeable difference in 
their behavior compared to the background strain. To evaluate whether Trolox 
treatment may rescue the strong behavioral and motoric phenotype in Rett mice, 
different tests were performed. To screen for general motor deficits the rotarod test 
was used (Fig. 6). To test the exploration behavior the open field was performed 
(Fig.7). The respective test area was cleaned thoroughly with 70% ethanol, after 
each mouse has been tested. 
 
The rotarod test is used to evaluate motor skill, motor learning, coordination and 
balance and has been proven to be a good paradigm for the screening of drugs 
which could modulate motor coordination (Dunham and Miya, 1957). Here, the 




rotarod system for mice (Ugo Basile, Comerio VA, Italy) with rotating rods, with a 
non-skid surface, was used (Fig. 6). Mice were placed on a rotating drum (3 cm 
diameter) and the time that each animal was able to maintain its balance on the rod 
was measured as latency to fall. During the test the rotation speed was continuously 
accelerated from 5 to 50 rpm over a period of 5 min (acceleration mode). Mice were 
tested on three consecutive days, in which the first day served to adapt the mice to 
the rotarod device. The second and third day were considered as the days the mice 




Figure 6: Rotarod – testing for motor function and learning 
The rotarod apparatus can be used to assess motor coordination and learning. Mice were 
placed on the rotating drum and the time that passed before the mice fell down was 
recorded. All rotarod experiments were performed in an acceleration mode (5 rpm to 50 
rpm in 5 min). 
 
General locomotor activity and anxiety-like behavior of mice were evaluated in a 
square open field arena of 45×45 cm (Fig. 7A). Mice were tested once in the arena 
for 5 min, and their motility was monitored online by a grid of 2 frames of 16 
infrared beams each covering the arena and tracked by using ActiTrack v2.7.13 
software (Panlab, Harvard Apparatus). The open field was divided in 3 different 
areas, periphery, corner and center by a virtual grid, defined in the tracking software 
(Fig. 7B). The horizontal activity of the animals, their total distance traveled, the 
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Figure 7: The open field – revealing exploration behavior 
The open field test can be used to test activity, anxiety-like behavior, and drug effects on 
motor and exploration behavior. (A) Open Field while running an experiment (B) Original 
tracking trace, with the 3 distinct zones, red = periphery; green = center; blue = corner. 
 
 
3.5. Unrestrained whole-body plethymography 
The regularity of breathing was measured by the unrestrained whole-body 
plethysmography (Drorbaugh and Fenn, 1955) in collaboration with Prof. Swen 
Hülsmann (Klinik für Anästhesiologie), who assisted in the detailed respiration 
analyses since he has a long lasting expertise in plethysmograpic research. Mice 
were placed in a chamber and allowed to breathe naturally, unrestrained and 
untethered (Fig. 8A). The system measures the tiny airflow that is exchanged in and 
out of the entire chamber due to the animal’s respiration. Recordings were 
performed by the software Ponemah v5 (Data Sciences International, St. Paul, 
Minnesota). Data were automatically analyzed by the threshold search event 
detection method of Clampfit 10.3 (Molecular Devices, Sunnyvale, CA). Breathing 
frequencies were calculated as the reciprocal of the averaged inspiratory interval. 
Furthermore, the irregularity score was determined as the normalized difference 




between a pair of subsequent breathing cycles (Barthe and Clarac, 1997; Telgkamp 
et al., 2002; Wegener et al., 2014). 
 
Figure 8: Unrestrained whole-body plethysmography – a measure of breathing 
(A) The unrestrained whole-body plethysmography chamber enables to monitor physiologic 
respiration parameters. (B) Sample traces display a time segment of ~4 s of a healthy WT 
mouse and a Mecp2-/y mouse with clear apnea.  
 
3.6. Preparation of acute brain slices 
Mice were anesthetized with ether in an exsiccator and decapitated with a surgical 
scissor. The brain was quickly but gently removed from the skull and placed in 
chilled ACSF for 1-2 min. Coronal brain sections of 400 µm were cut using a 
vibroslicer (Campden Instruments, 752M Vibroslice). Whole brain slices were 
separated in the sagittal midline and depending on the experiments they were 
either directly transferred to an interface recording chamber or to a separate 
submersion-style storage chamber. Slices were left subsequently undisturbed for at 
least 90 min, to recover from the slicing procedure before experiments were started.  
 
 
3.7. Blood parameters – Hematocrit and blood glucose level 
The hematocrit was measured from blood samples obtained directly after 
decapitation from the neck of the respective mouse. It represents the volume 
percentage of the corpuscular fraction in the blood. The packed cell volume can be 
determined by centrifuging blood in standardized hematocrit capillaries (Brand 
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GmbH) at 12000 RPM for 5 min (Mikro 220; Hettich Zentrifugen). Blood glucose 
levels of each mouse were obtained by using a blood glucose meter (Contour®; 
Bayer Diabetes care). 
 
3.8. Electrophysiology 
Electrophysiological recordings were performed in an Oslo style interface recording 
chamber. For the assessment of synaptic plasticity and seizure activity slices were 
kept at a temperature of 31-32°C whereas for hypoxia experiments the temperature 
was increased to 35-36°C. To make sure that the slices stay viable and yield stable 
responses over the recording time, they were constantly aerated with carbogen at a 
flow rate of 400 ml/min and supplied with oxygenated and prewarmed ACSF at a 
flow rate of 3-4 ml/min. Extracellular recording electrodes were pulled from thin-
walled borosilicate glass (GC150TF-10, Harvard Apparatus) on a horizontal electrode 
puller (Model P-97, Sutter Instruments). They were filled with ACSF, and their tips 
were trimmed to a resistance of ~5 MΩ. The stimulation electrode consisted of a 
bare stainless steel microwire (50 μm diameter, AM-Systems) soldered to a golden 
pin, which was connected to the photoelectric stimulus isolation unit (PSIU-6; Grass 
Instruments). Electrophysiological data were recorded with a locally constructed 
extracellular DC potential amplifier, constructed by the department’s electronics 
workshop. Data were sampled using an Axon Instruments Digitizer 1322A and 
PClamp 9.2 (Molecular Devices, Sunnyvale, CA) and analyzed by Clampfit 9.2 
software (Molecular Devices, Sunnyvale, CA). Field excitatory postsynaptic potentials 
(fEPSPs) were elicited by 0.1 ms unipolar stimuli (S88 stimulator with PSIU6 stimulus 
isolation units, Grass Instruments).  
 
All electrophysiological extracellular recordings were performed in the Cornu 
ammonis (CA) 1 or 3 area of the hippocampus. Synaptic strength of Schaffer 
collateral/CA1 synapses was analyzed by using input/output (I/O) curves. Theses I/O 
curves were recorded by varying stimulus intensity from 10 µA to 150 µA in 10 µA 
increments. For basal synaptic transmission, fEPSP amplitudes were normalized to 
the fiber volley to abolish differences between the individual slices and variations in 




electrode positioning. The detailed assessment of different types of synaptic 
plasticity was based on paired-pulse facilitation (PPF) and long-term potentiation 
(LTP) protocols. For PPF, stimulus intensity was set to the obtained half-maximum 
response and the interstimulus duration was varied in between 25 and 200 ms in 25 
ms increments. Stable LTP was induced by high-frequency stimulation; 100 Hz 
delivered in three trains of 1 s duration each and separated by 5 min intervals. 
Potentiated responses were then followed for an additional hour. The temperature 
was set to 31-32°C, to prevent triggering of hypoxic spreading depression by high 
frequently stimulation.  
 
Hypoxia-induced spreading depression (HSD) was triggered by switching the 
interface chamber’s gas supply from carbogen to nitrogen (95% N2 and 5% CO2). O2 
withdrawal induced HSD within 2-3 min and O2 was resubmitted 30 s after the onset 
of HSD. This ensured full recovery of the slices, but at the same time also allowed to 
fully develop its nadir.  
 
Seizure-like events (SLEs) were monitored in st. pyramidale of the CA3 region as this 
region is more prone to induction of such discharges than the CA1 subfield. 
Frequently recurring SLEs representing the epileptic discharges were induced by 
application of the K+-channel blocker 4-aminopyridine (4-AP), 100 µM for 15 min. 
 
 
3.9. Optical recordings 
For all optical recordings, analyses were performed in the st. radiatum, since 
synaptic function and HSD were assessed in this layer as well. A computer-controlled 
digital imaging system, composed of a polychromatic xenon-light source 
(Polychrome II, Till Photonics) and a sensitive charge-coupled device (CCD) SensiCam 
camera Imago QE (Till Photonics) attached to an upright epifluorescence microscope 
(Axiotech or Axioskop I) was used to image the flavin adenine dinucleotide (FAD) and 
nicotinamide adenine dinucleotide (NADH) autofluorescence as well as 
mitochondrial membrane potential (ψm). Acute hippocampal slices were kept in a 
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submersion-style chamber (30-33°C) and optical recordings were performed by 
using a 40x water immersion objective (Zeiss Achroplan, 0.8 NA).  
 
FAD and NADH autofluorescence was monitored side by side by alternating the 
excitation at 360 nm (NADH) and 445 nm (FAD). The frame rate was 5 s and the 
exposure times were set to 70 ms (NADH) and 40 ms (FAD). The autofluorescence 
was recorded using a 450 nm beam-splitter and a 510/80 nm bandpass filter 
(Duchen and Biscoe, 1992; Foster et al., 2006; Gerich et al., 2006) (Fig. 9).  
 
For ψm recordings (Emaus et al., 1986; Duchen, 1999) slices were bulk loaded with 
Rh123 (5 μM, 15 min) in a miniaturized staining chamber (Funke et al., 2007; Großer 
et al., 2012). Rh123 was used in quenching mode and therefore depolarization of 
mitochondria was indicated by an increase in Rh123 fluorescence (Emaus et al., 
1986). Rh123 was excited at 480 nm with a frame rate of 5 s and an exposure time 
of 5 ms. The emission was recorded using a 505 nm beam-splitter and a 535/35 nm 





Figure 9: Monitoring NADH and FAD  
NADH and FAD autofluorescence was recorded simultaneously from the same slice by 
alternating the excitation at 360 nm (NADH) and 445 nm (FAD). 
 




3.10. Statistics  
3-6 slices from at least 5 different brains of each genotype and treatment group 
were used for electrophysiological or optical recordings. For all behavioral 
experiments at least 10 mice of each group were tested. All numerical values are 
represented as mean ± standard deviation; the number of experiments (n) refers to 
the number of slices or mice analyzed. Significance of the observed changes was 
tested by SigmaStat 3.5 (Systat Software GmbH) one way ANOVA and a significance 
level of P=0.05. In the diagrams, statistically significant changes are indicated by 
asterisks (* P<0.05; ** P<0.01; *** P<0.001), and refer, if not mentioned otherwise, 
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4. Results 
In the present thesis, the aim was to verify whether mitochondrial metabolism 
changes in Mecp2-/y mice occur already at early postnatal stages and therefore may 
be a primary cause of Rett syndrome. Moreover, synaptic function and plasticity, 
neuronal excitability, hypoxia susceptibility, mitochondrial function as well as 
behavior and motor function of Mecp2-/y mice were assessed. The potential benefit 
of a scavenger treatment was evaluated in the presence of Trolox by bath 
application (in vitro) and by a chronic systemic Trolox treatment (in vivo). 
 
 
4.1. Higher oxidative burden already at early neonatal stages 
Fluorescence recordings have the advantage to diagnose the status quo of tissue 
metabolism. One can use these applications to acquire functional information of the 
tissue’s redox status. Since the mitochondrial metabolic coenzymes FAD and NADH, 
are autofluorescent, changes in the redox status can be monitored very elegantly 
without the use of further fluorophores (Duchen and Biscoe, 1992; Foster et al., 
2006). The fluorescence signals of these endogenous fluorophores can be used as 
indicators of tissue metabolism in injuries, especially due to hypoxia which may 
occur for example during apneas in Rett patients.  
 
In previous studies of our laboratory, a shift towards higher oxidation was detected 
in hippocampal slices of adult male Rett mice (Großer et al., 2012). Hence, the 
question arose, whether these mitochondrial changes already occur in early 
developmental stages. Therefore, dynamic recordings of FAD and NADH levels in 
acute hippocampal slices of neonatal mice (P7-10) were performed by monitoring 
tissue autofluorescence. An altered baseline FAD/NADH ratio was, indeed, already 
detectable in neonates (Table 1; Fig. 10A). In the st. radiatum of early neonatal 
Mecp2−/y slices the FAD/NADH ratio was increased by an average of 5.5% as 
compared to WT slices (Table 1). Moreover, pharmacological inhibition of the 
mitochondrial respiration by CN−, an inhibitor of the enzyme cytochrome c oxidase 





decreased FAD fluorescence, and therefore decreased the FAD/NADH ratio. 
However, significant differences in the CN−-evoked responses (100 μM or 1 mM,  
3 min) in the recorded autofluorescence among the genotypes were not observed. 
Although in the presence of CN− the FAD/NADH ratio still tended to be slightly more 
oxidized in Mecp2−/y st. radiatum as compared to WT slices (Table1; Fig.10A). 
 


























 2.12 ± 0.18; n = 16 2.22 ±  0.19; n = 26 
 
Table 1: Overview of basal and CN- mediated changes in mitochondrial metabolism 
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Figure 10: Imaging of tissue autofluorescence confirms a shift towards oxidation in 
neonatal Mecp2−/y hippocampus 
NADH and FAD autofluorescence was recorded from hippocampal slices by alternating the 
excitation at 360 nm (NADH) and 445 nm (FAD). (A) Ratiometric analysis of FAD and NADH 
autofluorescence allows a quantitative comparison of Mecp2−/y and WT slices. Already first 
alterations in FAD/NADH ratio were evident in slices from neonatal mice (P7–10). This 
confirms an early onset of disturbed mitochondrial function. Mitochondrial poisoning by  
100 µM or 1 mM CN− unequivocally abolished these baseline differences. The error bars 
indicate standard deviations of the plotted averages. (B,C) Sample traces from Mecp2-/y and 
WT of the resulting FAD/NADH ratio recorded from neonatal mice. Time scaling is identical 










4.2. Acute Trolox treatment 
To evaluate the potential outcome of a treatment of MeCP2-deficient neuronal 
networks with free radical scavengers, acute hippocampal tissue slices of adult 
Mecp2-/y and WT mice were incubated with 1 mM Trolox for at least 3 h  
(range 3–5 h). The detailed effects on synaptic function and synaptic plasticity, 
neuronal excitability, hypoxia susceptibility as well as mitochondrial function were 
then assessed in the continued presence of Trolox. To screen for a potential reversal 
of typical Rett syndrome symptoms, all experiments were performed at an age, at 
which Mecp2-/y mice have already developed clear phenotypic symptoms, i.e., 
around P45–50. 
 
4.2.1. Modulation of neuronal excitability and synaptic function 
 
4.2.1.1. Trolox treatment improves the hypoxia tolerance 
 
Findings from our group previously reported that MeCP2-deficient mouse 
hippocampal tissue shows an increased susceptibility to hypoxia i.e., the onset of the 
response to severe hypoxia was significantly hastened in Mecp2-/y hippocampal 
slices compared to WT slices. Hence, MeCP2-deficient neurons tolerated only a 
shorter duration of O2 shortage before neuronal membrane potentials collapsed 
(Fischer et al., 2009; Kron and Müller, 2010). 
 
In the present thesis, it could be confirmed that untreated Mecp2-/y slices generated 
HSD upon O2 withdrawal significantly earlier (~28%) as compared to WT slices (Table 
2; Fig. 11B). In contrast to this, the amplitude and duration of the HSD-associated 
extracellular DC potential shift did not differ among genotypes (Table 2; Fig. 11B). To 
screen whether the in vitro Trolox treatment would modulate the hypoxia tolerance 
in Mecp2-/y slices, HSD was induced upon Trolox bath application. Interestingly, 
Trolox treatment (Trolox recirculated in the interface chamber) clearly delayed the 
onset to HSD in Mecp2-/y slices but did not postpone the occurrence of HSD in WT 
slices (Table 2; Fig. 11B). 
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ACSF 146.77 ± 47; n = 37 106.15 ± 28; n = 32 











ACSF 16.43 ± 3; n = 37 17.85 ± 4; n = 32 










ACSF 66.29 ± 13; n = 37 68.38 ± 18; n = 32 
1 mM Trolox 67.44 ± 15; n = 37 71.97 ± 21; n = 36 
 
Table 2: Overview of the characteristic parameters of the HSD-associated DC potential 







Figure 11: Trolox improves the hypoxia tolerance of Mecp2-/y hippocampus 
(A) Sample traces from HSD recordings of Mecp2-/y and WT slices. Arrows indicate the start 
of severe hypoxia (O2.withdrawal). The reoxygenation of slices was resubmitted 30 s upon 
HSD onset. The response to severe hypoxia was significantly hastened in Mecp2-/y 
hippocampal slices as compared to WT slices. However, incubation of slices with Trolox 
selectively postponed HSD onset in adult Mecp2-/y slices to WT level. (B) Characteristic 
parameters of the HSD-associated DC potential shift such as amplitude of the negative DC 
shift, the time to onset and the duration revealed that Trolox postponed the onset of HSD in 




 33  
4.2.1.2. Input-output curve and paired pulse facilitation  
Several studies showed that synaptic plasticity is impaired in Rett mice (Asaka et al., 
2006; Moretti et al., 2006; Guy et al., 2007; Fischer et al., 2009). Hence, the impact 
of Trolox on various types of synaptic modulation was analyzed. To assess basal 
synaptic function and synaptic short-term plasticity, recordings of evoked fEPSPs 
were performed in the st. radiatum of the CA1 subfield of the hippocampus (Fig. 12). 
 
For basal synaptic transmission, fEPSP amplitudes were normalized to the fiber 
volley to abolish differences between the individual slices and variations in electrode 
positioning. Under control conditions, Mecp2-/y slices (n = 37) showed significantly 
(~44%) higher fEPSP/fiber volley ratios than WT slices (n = 50) at all stimulation 
intensities tested (Fig. 12A), which indicates an increased postsynaptic 
responsiveness and neuronal hyperexcitability. Trolox treatment of slices abolished 
the genotypic differences in fEPSP/fiber volley ratios, by decreasing the responses in 
Mecp2-/y slices (n = 43) to those levels observed in untreated and treated WT slices. 
In WT slices, Trolox did not induce any significant changes in the fEPSP/fiber volley 
ratio (n = 44).  
 
Synaptic short-term plasticity was assessed as PPF based on twin-pulse stimulation 
(Fig. 12B). Stimulation intensity was adjusted to evoke half-maximum response 
amplitudes and the interpulse interval was varied stepwise between 25 and 200 ms. 
While this potentiated the amplitude of the 2nd fEPSP in WT slices to 184.0 ± 34.4% 
(n = 52) of control, Mecp2-/y slices showed a significantly less pronounced fEPSP 
facilitation to only 165.9 ± 35.7% (n = 35) for the shortest interpulse interval tested 
(25 ms, Fig. 12B). Trolox treatment abolished this moderate genotypic difference in 
short-term plasticity at the 25 ms interval, but otherwise did not induce any 








Figure 12: Trolox dampens neuronal hyperexcitability 
(A) A significantly increased excitability in Mecp2-/y slices was found as compared to WT at 
all stimulation intensities. Trolox abolished this genotypic difference. The plotted fEPSP 
amplitudes are normalized to the fiber volley of the respective slice. (B) PPF, a measure of 
short-term plasticity, was elicited over a range of interpulse intervals. The degree of PPF in 
hippocampal slices from Mecp2-/y mice was lower than that in WT slices for the shortest 
interpulse-interval tested. Upon Trolox treatment this genotypic minor difference was no 
longer detectable. For clarity standard deviations are only included for untreated Mecp2-/y 
and Trolox treated Mecp2-/yslices. 
 
4.2.1.3 LTP is rescued by in vitro application of Trolox 
LTP in the CA1 region of the hippocampus is an activity-dependent long lasting 
increase in the activity of neurotransmission that requires, among others, N-Methyl-
D-aspartic acid (NMDA) receptor activation, and is thought to represent a cellular 
mechanism underlying some forms of learning and memory (Bliss and Collingridge, 
1993; Lynch, 2004). Hence, alterations in the excitatory synaptic plasticity and 
strength could be considered as one cause contributing to the cognitive and 
functional deficits seen in Rett patients and has been also already shown by several 
other groups to be impaired in Rett mouse models (Asaka et al., 2006; Moretti et al., 
2006). Based on this knowledge, the potential modulation of short-term 
potentiation (STP) and LTP by Trolox was assessed in this study.  
 
Extracellular field potential recordings were performed in the CA1 of hippocampal 
slices with or without Trolox in the bath solution for the duration of experiments. 
Results 
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STP and LTP were induced by high-frequency stimulation (Fig. 13). The fEPSPs, taken 
after a 10-minute baseline, were significantly different between WT and Mecp2-/y 
slices. In detail, STP in Mecp2-/y was significantly reduced (Table 3; Fig. 13B) and 1h 
after LTP induction (range 50–60 min), fEPSPs were still potentiated in WT slices, but 
showed a less intense degree of LTP in Mecp2-/y (Table 3; Fig. 13B). Trolox, however, 
improved the extent of both, STP and LTP in Mecp2-/y slices which was represented 
by a stable LTP even 1 h after tetanic stimulation (Table 3; Fig. 13B,C). Moreover, a 
stimulating effect of Trolox on WT slices was not observed. Instead, the extent of 
STP slightly declined and LTP showed a tendency of being less pronounced in the 
presence of Trolox than in untreated WT slices (Table 3; Fig. 13B,C).  
 





] ACSF 238.2± 62; n = 12 158.7 ± 38; n = 11 





] ACSF 179.4 ± 31; n = 12 143.3 ± 19; n = 11 
1 mM Trolox 155.8 ± 33,; n = 9 181.1 ± 32; n = 10 
 










Figure 13: Improved STP and LTP after Trolox application 
(A) Sample fEPSPs recorded from Mecp2-/y and WT slices in ACSF under baseline conditions, 
immediately after the 3rd high-frequency stimulation (STP) and 1 h after inducing 
potentiation (LTP). Please note the stimulus artifacts are truncated. For clarity, error bars 
are plotted for every second data point of WT and Mecp2-/y slices only. (B) STP and LTP were 
significantly impaired in Mecp2-/y compared to WT slices. Trolox, however, improved STP 
and LTP in Mecp2-/y slices to levels seen in untreated WT slices.  In WT, Trolox dampened the 
extent of LTP to conditions typically found in untreated Mecp2-/y slices. The number of slices 
analyzed is indicated below each bar (C) LTP was induced by three consecutive trains of 100 
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4.2.2. Anticonvulsive potential of Trolox 
Rett patients show an increased incidence of epileptic seizures (Hagberg et al., 1983; 
Steffenburg et al., 2001) and increased neuronal excitability is also evident in 
MeCP2-deficient mice (Medrihan et al., 2008; Fischer et al., 2009; Calfa et al., 2011; 
Toloe et al., 2014). Since Trolox successfully dampened neuronal hyperexcitability in 
Mecp2-/y slices, the potential anticonvulsive effect of Trolox was tested. Seizure 
activity was provoked by the K+-channel inhibitor 4-AP (Rutecki et al., 1987) and the 
resulting SLEs were recorded extracellularly in st. pyramidale of the CA3 subfield, as 
hyperexcitability in Rett mouse hippocampus arises particularly in this region (Calfa 
et al., 2011).  
 
Extracellular recordings in CA3 from slices bathed in 4-AP (100 μM, 35 min) triggered 
SLEs which long-lasting discharges, which were analyzed in detail for the last 5 min 
of each experiment (Table 4; Fig. 14B). SLEs arose within similar times to onset in WT 
and Mecp2-/y slices. Trolox treatment (1 mM, 3–5 h) showed a tendency to postpone 
the onset of SLEs in WT slices only but the frequency of discharges was not 
significantly affected (Table 4; Fig. 14B). The duration of the individual SLEs was 
variable and showed only a tendency to decrease upon Trolox treatment in both WT 
and Mecp2-/y slices (Table 4; Fig. 14C). It should be noted, that in some experiments 























ACSF 555.7 ± 124.3; n = 11  554.1 ± 136.2; n = 12 














ACSF 135.5 ± 87.3; n = 11 105.3 ± 77.8; n = 12 













ACSF 361.5 ± 254.9 ; n = 11 428.6 ± 192.7; n = 12 
1 mM Trolox 278.2 ± 176.2; n = 11 293.1 ± 187.1; n = 9 
 
Table 4: Detailed listing of the characteristic features of SLEs shift such as time to onset, 
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Figure 14: Trolox only shows a general tendency to dampen seizure susceptibility 
(A) Sample traces of SLEs recorded from an untreated Mecp2-/y slice in CA3 st. pyramidale. 
The lower trace shows a SLE (red box) at a stretched time scale. (B) The time to onset and 
the SLE frequency, plotted as the number of discharges within the analyzed time interval of 
5 min, did not differ among Mecp2-/y and WT slices under control conditions and Trolox 
application. Trolox statistically tended to postpone the onset of discharges in WT slices as 
compared to untreated slices. (C) Significant genotypic differences in the duration of the 
individual SLEs were not observed. Yet, Trolox tended to reduce the duration of the 












4.2.4. Modulation of mitochondrial function 
To check whether Trolox modulates mitochondrial function in adult Rett mice tissue, 
mitochondrial metabolism was assessed by imaging FAD and NADH 
autofluorescence (Duchen and Biscoe, 1992; Foster et al., 2006) and mitochondrial 
membrane potential (Δψm) by recording Rh123 fluorescence (Emaus et al., 1986; 
Duchen, 1999). These imaging experiments were performed on the tissue level in st. 
radiatum of the CA1 subfield of acute adult tissue slices (Fig. 15A), as also synaptic 
function was analyzed in this layer. 
 
Under baseline conditions the ratio of FAD/NADH autofluorescence was slightly 
increased in Mecp2-/y hippocampus, which indicates an intensified basal 
mitochondrial respiration. The FAD/NADH ratio was increased slightly by an average 
of 10.9% in Mecp2-/y slices as compared to WT (Table 5; Fig. 15A,B). Trolox did not 
mediate any statistically significant changes in these metabolic parameters of either 
WT or Mecp2-/y slices. Furthermore, also the influence of pharmacological inhibition 
of the respiratory chain by low and high doses of CN- (100 μM, 1 mM) was 
examined. The application of CN- for 3 min caused a dose-dependent decrease in 
FAD/NADH ratio which did not differ between WT and Mecp2-/y slices (Table 5; Fig. 
15C). Trolox, however, significantly dampened the inhibitory effects of both low and 
high CN- concentrations in Mecp2-/y slices. No such effects were evident in WT slices 
(Fig. 15C). These findings suggest that Trolox may reduce the susceptibility of 
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1.92  ± 0.1; n = 19 
 
2.09  ± 0.2; n = 17 














ACSF 1.53 ± 0.1; n = 19 1.63  ± 0.2; n = 17 












ACSF 1.27  ± 0.1; n = 19 1.35  ± 0.2; n = 17 
1 mM Trolox 1.29  ± 0.1; n = 15 1.44  ± 0.3; n = 19 
 
Table 5: Summary of basal and CN--mediated changes in mitochondrial metabolism with 













Figure 15: Trolox only slightly affects mitochondrial metabolism  
(A) Sample traces of the decreases in FAD/NADH ratio induced by CN- in untreated WT and 
Mecp2-/y slices recorded in CA1 st. radiatum. Gray and red bars indicate the time points and 
duration of drug application to the WT and Mecp2-/y slice, respectively. (B) Analyses of 
Mecp2-/y slices revealed an increased FAD/NADH baseline ratio, indicating intensified 
mitochondrial respiration. Application of Trolox did not affect basal respiration. Bar shading 
and patterns are identical for panels B and C. (C) Mitochondrial challenge by CN- (3 min) 
inhibits the respiratory chain, and thereby decreases the FAD/NADH ratio. Trolox slightly 








 43  
In addition, earlier experiments of our group revealed a partly depolarized Δψm in 
adult Mecp2-/y hippocampal slices (Großer et al., 2012). Corresponding Rh123 
recordings of mitochondrial Δψm changes were performed. Less intense Δψm 
responses in Mecp2-/y slices upon mitochondrial uncoupling by 5 μM FCCP than in 
WT slices (Table 6; Fig. 16B,C), and thus a less negative Δψm could be confirmed in 
this thesis. Upon Trolox treatment, both WT and Mecp2-/y slices tended to show 
slightly more intense Rh123 responses to FCCP. Therefore, the genotypic difference 
became smaller and was no longer statistically significant (Table 6; Figure 16C). 
 
Cyanide-mediated inhibition of mitochondrial respiration evoked marked increases 
in Rh123 fluorescence, indicating strong mitochondrial depolarization (Fig. 16D). 
Rh123 changes were normalized to the complete mitochondrial depolarization 
induced by FCCP. Genotypic differences were, however, not observed in the 
responses of Mecp2-/y and WT slices to low mitochondrial challenge and high CN- 
doses (Fig. 16D). Trolox did not modulate the extent of the CN--induced 
mitochondrial depolarization. Only in the case of high CN- concentrations, the Rh123 
responses tended to be slightly higher in Trolox-treated Mecp2-/y slices. 
 






















 ACSF 0.61 ± 0.20; n = 20 0.47 ± 0.19; n = 20 
1 mM Trolox 0.67 ± 0.23; n = 15 0.56 ±  0.19; n = 17 
 










Figure 16: No effects of Trolox on mitochondrial metabolism and function 
(A) Overview of a Rh123-labeled slice viewed under transillumination. The zoomed field of 
view (red box) used for the Rh123 recordings. A typical region of interest (white box) is 
shown under 485 nm excitation. (B) Superimposed sample traces of the relative Rh123 
fluorescence changes (F/Fo) evoked by CN
- and FCCP in a Trolox-treated WT and Mecp2-/y 
slice. Drug treatment of the WT and Mecp2-/y slice is indicated by gray and red bars, 
respectively. (C) Rh123 responses to FCCP mediated uncoupling, as referred to baseline 
conditions. Note that Mecp2-/y slices show less intense Rh123 responses. Trolox application, 
however, diminished this difference among the two genotypes. (D) Summary of CN--evoked 
and FCCP-mediated increases in Rh123 fluorescence as referred to baseline.  
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4.3. Systemic Trolox treatment  
To evaluate the potential benefit of an in vivo treatment on the phenotype of 
Mecp2-/y mice and therefore also on MeCP2-deficient neuronal networks with the 
free radical scavenger Trolox, WT and Mecp2-/y mice were treated with either PBS, 
10 mg/kg or 40 mg/kg of Trolox by i.p. injections. Injections were performed every 
second day and the entire study was blind until the last mouse had been measured 
and analyzed. Injections were conducted every second day to minimize the risk of 
peritonitis, embolism, adhesions, infections and to reduce stress. Mice tolerated the 
injections well and became less nervous with time. From time to time, the abdomen 
of a random chosen mouse was opened and inspected for changes in the 
intraperitoneal cavity. No obvious injuries could be ever observed.  
 
As clearly early changes in the mitochondrial function have been seen in Rett mice, a 
resulting pharmacotherapeutical treatment should start already at early postnatal 
and presymptomatic stages. Mice were, therefore, injected from day 10/11 after 
birth. To be able to screen for a potential reversal of typical Rett syndrome 
symptoms, also in the systemically treated mice treatment was continued up to  
P45–50. Furthermore, to get a full picture of the treatment outcome, a multitude of 
parameters such as effects of the treatment on synaptic function and plasticity, 
neuronal excitability, hypoxia susceptibility as well as mitochondrial function was 
then assessed in the isolated tissue of these mice. These studies were performed as 
in the previous in vitro experiments. Also motor performance and exploration 










4.3.1. Systemic parameters 
Blood glucose level, hematocrit, Body Mass Index (BMI) and the body weight over 
injection time were assessed to define the efficacy of the in vivo Trolox treatment 
also on systemic parameters. 
 
Increased glucose utilization in Rett patients confirmed alterations in glucose 
metabolism (Villemagne et al., 2002). In Mecp2-/y mice, a loss of MeCP2 function has 
been shown to increase insulin levels, decrease insulin signaling and therefore to 
result in a dissociation of insulin levels and the appropriate metabolic effects of 
insulin on glucose regulation (Pitcher et al., 2013). In the present study, the blood 
glucose level in Mecp2-/y mice, treated with PBS only, was significantly lower by 
about 30% as compared to the WT. Injection of Mecp2-/y mice with either low or 
high dose of Trolox increased the blood glucose to levels seen in the respective WT 
mice (Table 7; Fig. 17A), i.e., rescued this systemic parameter. 
 
To test for a systemic adaptation of Mecp2−/y mice to the repeated apnea-related 
systemic hypoxic episodes, the hematocrit was determined. It was measured from 
blood samples collected during dissection, and was significantly higher in all 
Mecp2−/y treatment groups compared to WT mice. This suggests that Mecp2−/y mice, 
even after receiving chronic Trolox treatment, still underwent repeated systemic 
hypoxic episodes during their life (Table 7; Fig. 17B).  
 
The BMI is a measure of the relative weight based on an individual's body size and 
does not consider body tissue composition. Trolox treatment did not evoke any 
changes in the BMI among the different treatment groups of both genotypes, but 
revealed, as expected from the reduced growth of Mecp2-/y mice, a significant lower 
BMI in all Mecp2-/y mice compared to WT mice (Table 7; Fig. 17C). The growth of 
mice was followed in detail as body weight had to be determined every second day 
for Trolox injection dosing. 
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In general, Mecp2-/y mice appeared normal at birth but started to develop 
significantly reduced body weights by around 3 weeks of age (Fig. 17D). The final 
body weight (~P46) of Mecp2-/y mice was about half of the weight of WT mice. 
 
 
















 PBS only 14.1 ± 2.4; n = 17 10.1 ± 3.3; n = 16 
10 mg/kg Trolox 12.7 ± 2.3; n = 16 11.8 ± 2.0; n = 16 









]    
PBS only 43.5 ± 2.5; n = 17 47.9 ± 3.6; n = 16 
10 mg/kg Trolox 42.3 ± 3.3; n = 16 47.5 ± 3.3; n = 19 









   
PBS only 0.34 ± 0.02; n = 17 0.29 ± 0.03; n = 15 
10 mg/kg Trolox 0.34 ± 0.02; n = 16 0.29 ± 0.03; n = 18 
40 mg/kg Trolox 0.34 ± 0.03; n = 22 0.29 ± 0.02; n = 13 
 
Table 7: Comparison of systemic parameters such as blood glucose, hematocrit and BMI 

















Figure 17: Systemic parameters do not reveal general improvements by in vivo Trolox 
treatment 
(A) Blood glucose level of Mecp2-/y mice was significantly decreased in the PBS only group, 
but was rescued upon Trolox treatment. (B) The hematocrit value was significantly 
increased in all Mecp2-/y mice indepent of the treatment received. (C) The BMI was 
significantly decreased in all Mecp2-/y mice. (D) Mecp2-/y mice appeared normal at birth but 
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4.3.2. Motor and exploration behavior 
 
4.3.2.1. Motor dysfunction persists in Mecp2-/y mice after Trolox    
treatment  
 
Rett patients as well as Rett mice show various and complex motor impairments. To 
determine whether Trolox treatment has any positive effect on motor performance 
and motor learning the accelerating rotarod, a standard paradigm widely used to 
evaluate the motor coordination, was run. The rotarod test was performed on 3 
consecutive days, in which the first day was considered to be the habituation day. 
Motor learning is expected to occur between day 2 (trial day 1) and day 3 (trial day 
2) and revealed an average increase in running time of ~15 % in WT mice regardless 
of the treatment (Table 8; Fig. 18). All Mecp2-/y mice groups showed a poor 
performance on the rotarod with a significantly decreased latency to fall off the rod 
compared to the respective WT group. Between day 2 (trial day 1) and day 3 (trial 
day 2) Mecp2-/y mice increased their skills by an average of 6 % in the PBS and low 
dose Trolox treated group, whereas the high dose Trolox treated group even 


































 PBS only 147.5 ± 55.2; n = 17 66.5 ± 39.4; n = 17 
10 mg/kg Trolox 157 ± 54.9; n = 15 67.6 ± 45.3; n = 22 















   
PBS only 162.2 ± 48.2; n = 17 76.2 ± 50.2; n = 17 
10 mg/kg Trolox 170.3 ± 47.7; n = 15 92.6 ± 45.4; n = 22 
















   
PBS only 185.7 ± 49.9; n = 17 80.5 ± 52.9; n = 17 
10 mg/kg Trolox 198.3 ± 50; n = 15 98.9 ± 49; n = 22 
40 mg/kg Trolox 175.6 ± 67.3; n = 20 81.4 ± 28.4; n = 14 
 





Figure 18: Mecp2-/y mice show a decline in motor skills 
The latency to fall was recorded as a measure of motor performance. Comparison of the 
latency to fall revealed the significant difference in the motor performance between  
Mecp2-/y and WT mice but not in between the different treatment groups. All groups of 
mice, except the high dose Mecp2-/y group, improved with training and were thus able to 
learn the task.  
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4.3.2.2. Mecp2-/y mice display a lower activity but have a normal 
exploration behavior after treatment with Trolox 
Since the hippocampus has been reported to be crucially involved in exploration 
(O'Keefe and Dostrovsky, 1971), exploratory behavior and locomotor activity of 
Mecp2-/y mice and respective WT mice was determined in an open field arena. The 
open field test paradigm mimicked the natural conflict in mice between exploring a 
novel environment and avoiding an illuminated open area. No obvious differences in 
the relative time spent within the 3 zones could be detected between Mecp2-/y and 
the respective WT mice. Based on this finding, it seems unlikely that a reduced 
exploratory activity is due to higher anxiety levels in Mecp2-/y mice (Table 9; Fig. 
19A). Overall, Mecp2-/y mice, independent of the received treatment, showed lower 
activity as measured by the total distance traveled as well as a lower mean velocity. 
In part, this may be a consequence of motoric deficits of these mice (Table 9; Fig. 
19B,C). Also the fact that Mecp2-/y showed longer resting times suggests motor 






























PBS only 39.3 ± 7.9; n = 13 42.9 ± 17.2; n= 16 
10 mg/kg Trolox 32.4 ± 9.2; n = 16 42.6 ± 9; n= 15 









   
PBS only 7.6 ± 4.2; n = 13 8.7 ± 12.9; n = 16 
10 mg/kg Trolox 6.9 ± 3.9; n = 16 7.3 ± 7.5; n = 15 








   
PBS only 53.2 ± 10.4; n = 13 48.4 ± 17.9; n = 16 
10 mg/kg Trolox 60.5 ± 9; n = 16 50.7 ± 13.5; n = 15 










   
PBS only 17.4 ± 3.6; n = 13 12.6 ± 5.2; n = 16 
10 mg/kg Trolox 17.9 ± 5; n = 16 11.8 ± 3.9; n = 15 














   
PBS only 5.8 ± 1.2; n = 13 4.2 ± 1.7; n = 16 
10 mg/kg Trolox 5.9 ± 1.7; n = 16 3.9 ± 1.3; n = 15 












   
PBS only 25.5 ± 8.4; n= 13 38.3 ± 18.9; n= 16 
10 mg/kg Trolox 23.9 ± 8.3; n= 16 38.5 ± 14.2; n= 15 
40 mg/kg Trolox 32.2 ± 13.7; n= 19 37.3 ± 13.3; n= 14 
 
Table 9: Effect of Trolox treatment on the mobility in the open field 
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Figure 19: Mecp2-/y mice are less active in the open field arena 
General locomotor activity levels and anxiety in in vivo treated Mecp2-/y and WT mice was 
tested after ~35-40 days of treatment. (A) Mecp2-/y and WT males did not differ in their 
exploration behavior. Mecp2-/y mice, independent of the treatment, visited the different 
zones in the same way as WT mice. Only the low dose treated Rett mice spent significantly 
longer times in the periphery and the corners. (B) All treated Mecp2-/y mice groups traveled 
shorter distances compared to WT mice. (C) Furthermore, Mecp2-/y mice traveled at a 
significantly lower speed compared to WT mice. (D) Moreover, Mecp2-/y mice showed 














4.3.3. Breathing pattern is not affected by in vivo Trolox treatment  
Rett patients undergo different severe forms of breathing disturbances including 
breath holding, air swallowing, hyperventilation and apnea. Also in various Rett mice 
a corresponding irregular breathing pattern has been confirmed (Julu et al., 2001; 
Viemari et al., 2005; Katz et al., 2009). 
 
To evaluate the breathing pattern of Trolox treated mice, in vivo plethysmoraphy of 
unrestrained and conscious mice was performed. As expected, breathing 
irregularities such as breathing arrests lasting > 1 s, breaths per min and the 
irregularity score significantly differed among Mecp2-/y mice and WT mice. While 
breathing arrests (apneas) occurred more often in Mecp2-/y mice compared to WT 
(Table 10; Fig. 20B), the breathing frequency was significantly reduced in Mecp2-/y 
mice (Table 10; Fig. 20C). Also the irregularity score, i.e., the variability in duration of 
respiratory cycles, was significantly higher in Mecp2-/y mice than in WT mice (Table 
10; Fig. 20D). Any changes or noticeably improvements in the breathing pattern of 
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PBS only 0.6 ± 1; n = 15 8.3 ± 9.7; n = 16 
10 mg/kg Trolox 0.2 ± 0.4; n = 15 9 ± 8.7; n = 15 











   
PBS only 399.7 ± 37.4; n = 15 315.9 ± 70; n = 16 
10 mg/kg Trolox 432.1 ± 55.4; n = 15 283.6 ± 53.9; n = 15 












   
PBS only 0.4 ± 0.1; n = 15 0.55 ± 0.2; n = 16 
10 mg/kg Trolox 0.3 ± 0.04; n = 15 0.53 ± 0.2; n = 15 
40 mg/kg Trolox 0.3 ± 0.1; n = 18 0.59 ± 0.1; n = 14 
 







Figure 20: Breathing pattern of treated Mecp2-/y and WT mice 
(A) Sample traces of the breathing pattern typically seen during whole-body 
plethysmography in the WT and Mecp2-/y PBS only group. Breathing arrests in Mecp2-/y mice 
are clearly visible. (B) The number of breathing arrests exceeding 1 s is significantly 
increased in all treatment groups of Mecp2-/y mice compared to WT mice. (C) The breathing 
frequency was significantly decreased in all Mecp2-/y mice compared to WT mice. (D) The 
irregularity score was significantly increased in all Mecp2-/y mice compared to WT mice. For 
all parameters, significant differences could be observed among genotypes but not in 
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4.3.4. Modulation of neuronal excitability and synaptic function  
 
4.3.4.1. Increased hypoxia tolerance by low dose Trolox treatment of 
Mecp2-/y mice 
In the in vitro trials, a single, acute application of Trolox improved the hypoxia 
tolerance of Mecp2-/y hippocampal slices. To screen for differences in the hypoxia 
susceptibility between injected Mecp2-/y and WT mice, HSD was triggered by O2 
withdrawal in hippocampal tissue, isolated from these mice. Surprisingly, comparing 
genotypes revealed that the characteristic HSD parameters such as amplitude, 
duration, and time to onset, determined for Mecp2-/y did not differ significantly from 
those obtained in WT mice. This is in contrast to the untreated mice studied earlier. 
Only in hippocampal slices of the low dose Trolox-treated Mecp2-/y group, the time 
to onset of HSD was significantly increased as compared to the respective WT group 
as well as compared to the Mecp2-/y PBS only group (Table 11; Fig. 21). HSD 
amplitude and duration were unchanged among the genotypes and treatment 
groups (Table 11). To check, if the loss of genotypic differences is due to handling, 
seasonal or breeding reasons, HSD was again triggered in slices from untreated 
Mecp2-/y and WT mice (n= 4; each) and revealed again hastened onset of HSD by 






























 PBS only 144.2 ± 32.9; n = 27 138.5 ± 24.3; n = 28 
10 mg/kg Trolox 127.9 ± 35.9; n = 27 173.6 ± 58.9; n = 26 












   
PBS only 14.9 ± 2.8; n = 27 15.7 ± 3.5; n = 28 
10 mg/kg Trolox 14.7 ± 3.9; n = 27 14.4 ± 3.5; n = 26 










   
PBS only 69.5 ± 12.7; n = 27 138.5 ± 24.3; n = 28 
10 mg/kg Trolox 63.3 ± 13.3; n = 27 64 ± 9.8; n = 26 
40 mg/kg Trolox 70.8 ± 20.4; n = 25 67.4 ± 11.1; n = 21 
 
Table 11: Overview of the characteristic parameters of the HSD-associated DC potential 
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Figure 21: Low dose Trolox treatment improves hypoxia tolerance in slices of Mecp2-/y  
Sample traces from extracellular DC potential recordings in CA1 st. radiatum of Mecp2-/y and 
WT slices. Arrows indicate the time point of extracellular O2 withdrawal. The reoxygenation 
of slices was started 30 s upon HSD onset. B) Contrary to what was seen earlier in untreated 
mice, the response to severe hypoxia did not longer differ in Mecp2-/y hippocampal slices as 
compared to WT slices. Even the PBS only group did not any reveal differences in HSD onset. 
Nevertheless, the low dose Trolox treatment significantly postponed the onset of HSD in 
Mecp2-/y slices as compared to the respective treated WT group but did not affect the other 















4.3.4.2. No obvious changes in basal synaptic transmission  
 
To test for treatment related changes in the general synaptic function, the I/O 
curves of the Schaffer collateral/CA1 synapses as well as the degree of synaptic 
short-term plasticity was assessed. Recordings of evoked fEPSPs were again 
performed in the st. radiatum of the CA1 subfield of the hippocampus. For basal 
synaptic transmission, fEPSP amplitudes were normalized to the fiber volley to 
cancel out differences between the individual slices and variations in electrode 
positioning. However, no significant difference in shape or amplitude ratio could be 
observed between Mecp2-/y and WT mice (n = 16-24 slices) (Fig. 22), which suggests 
an unaltered basal synaptic transmission. Earlier observed differences in untreated 
mice were also not found upon chronic treatment in the PBS only groups. 
 
Figure 22: No obvious effects on neuronal excitability by in vivo Trolox treatment 
Acute hippocampal tissue slices of injected Mecp2-/y and WT were used to assess neuronal 
excitability and basal synaptic function. I/O curves were recorded by a stepwise increase in 
the stimulation intensity from 10–150 µA. Genotypic differences and/or differences among 
the different treatment groups in neuronal excitability were not observed. 
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4.3.4.3. No alterations in paired-pulse facilitation in Mecp2-/y and WT 
mice 
PPF is a presynaptic form of short-term synaptic plasticity resulting from enhanced 
residual calcium in the presynaptic terminal release in fEPSP response to two stimuli 
delivered at short interpulse intervals. To quantify the effects of in vivo Trolox 
treatment on the short-term plasticity, PPF was evaluated in Mecp2-/y and WT slices 
(Fig. 23). PPF was measured in response to 8 different interpulse intervals ranging 
from 25 to 200 ms in 25 ms increments. In all treatment groups, PPF recordings from 
Mecp2-/y and WT slice were indistinguishable at all intervals (n = 16-24 slices)  
(Fig. 23). 
 
Figure 23: Short-term plasticity is not modulated by Trolox treatment 
PPF was quantified as a paradigm for synaptic short-term plasticity in Mecp2-/y and WT mice. 
This twin-pulse stimulation was performed at various interstimulus intervals (25–200 ms) 
and quantified as the ratio of the second fEPSP to the first fEPSP amplitude. No significant 






4.3.4.4. Improvement in Mecp2-/y hippocampal long-term synaptic 
plasticity by low dose Trolox treatment 
Synaptic long-tem plasticity was induced in acute hippocampal slices obtained from 
the treated Mecp2-/y and WT mice and a potential modulation of STP and LTP by 
chronic Trolox-treatment was assessed. As described earlier, STP and LTP were 
induced by 3 trains of high-frequency stimulation. Induction of LTP led to a robust 
potentiation of the fEPSP amplitudes in slices from Mecp2-/y and WT mice regardless 
the treatment received. Nevertheless, slices from Mecp2-/y mice, treated with PBS 
only or high dose Trolox tended to have an impaired STP but the same characteristic 
LTP when compared to the respective WT group. In contrast, treatment with the low 
dose of Trolox significantly improved the STP and also tended to induce a more 
pronounced LTP (Table 12; Fig. 24C). 
 




PBS only 1.75 ± 0.42; n = 14 1.56 ± 0.51; n = 11 
10 mg/kg Trolox 1.65 ± 0.36; n = 12 2.03 ± 0.53; n = 15 




   
PBS only 1.56 ± 0.41; n = 14 1.55 ± 0.36; n = 11 
10 mg/kg Trolox 1.59 ± 0.35; n = 12 1.72 ± 0.35; n = 15 
40 mg/kg Trolox 1.57 ± 0.28; n = 15 1.66 ± 0.25; n = 12 
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Figure 24: Unaltered STP and LTP in Mecp2-/y and WT mice after receiving chronic Trolox or 
PBS-treatment 
(A) Sample traces of fEPSPs recorded for PBS treated WT mice under baseline conditions, 
immediately after the 3rd high-frequency stimulation (STP) and 1 h after inducing 
potentiation (LTP). Stimulus artifacts are truncated. (B) STP and LTP were no longer impaired 
in all treated Mecp2-/y slices as compared to WT slices. For clarity, error bars are not 
included. LTP was induced by three consecutive trains of 100 Hz stimuli, lasting 1 s each (see 
arrow marks). (C) Comparison of the extent STP and LTP induced in the different groups 
revealed that STP improved in the low dose treated Mecp2-/y mice. Further differences 





4.3.5. Optical recordings of mitochondrial metabolism 
Rett syndrome has clinical similarities to other disorders associated with 
mitochondrial dysfunction (Pieczenik and Neustadt, 2007) and previous findings 
indicated abnormalities in mitochondrial metabolism of Mecp2-/y mice (Großer et al., 
2012). To assess whether in vivo Trolox-treatment had an effect on mitochondrial 
metabolism, FAD/NADH autofluorescence recordings were performed. The basal 
mitochondrial metabolism, analyzed by FAD/NADH ratio, was not altered between 
Mecp2-/y and WT mice. Furthermore, pharmacological inhibition of the 
mitochondrial respiration by CN- also did not reveal differences in the 
autofluorescence responses among genotypes. Moreover, in vivo treatment with 
Trolox did not mediate any changes in mitochondrial metabolism (Table 13; Fig. 25). 
Therefore, at least negative effects of chronic treatment on mitochondria can be 
excluded. 
 









PBS only 0.66 ± 0.13; n = 20 0.66 ± 0.13; n = 23 
10 mg/kg Trolox 0.59 ± 0.09; n = 25 0.67 ± 0.09; n = 24 














   
PBS only 0.57 ± 0.1; n = 20 0.57 ± 0.10; n = 23 
10 mg/kg Trolox 0.52 ± 0.7; n = 25 0.56 ± 0.05; n = 24 












   
PBS only 0.50 ± 0.10; n = 20 0.5 ± 0.12; n = 23 
10 mg/kg Trolox 0.45 ± 0.06; n = 25 0.48 ± 0.05; n = 24 
40 mg/kg Trolox 0.52 ± 0.07; n = 23 0.52 ± 0.13; n = 20 
 
Table 13: FAD/NADH baseline ratio and effects of challenging mitochondria with CN- after 
in vivo treatment 
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Figure 25: Mitochondria are not affected in Trolox-treated mice 
NADH and FAD autofluorescence was recorded from hippocampal slices by alternating the 
excitation at 360 nm (NADH) and 445 nm (FAD). Differences in the basal mitochondrial 
respiration or differing responses to chemical mitochondrial challenging by CN- were not 
obvious in slices from adult treated Mecp2-/y and WT mice. Therefore, negative effects of 
Trolox on mitochondria can be clearly excluded.  
 
4.4. Survival of Trolox-treated mice 
In total, 152 mice (75 Mecp2-/y and 77 WT mice) received a blinded PBS or Trolox 
treatment. During that treatment period, 8 Mecp2-/y mice died before they reached 
an age of 40 days (~10%). In detail, mice died between age P15 and P38. In 
comparison, the survival rate of untreated Mecp2-/y mice in our Rett mouse colony 
was nearly the same and therefore comparable with the findings in treated mice. A 
negative impact of the chronic treatment procedure (i.p. injections and frequent 
handling) on the survival can be excluded. Nevertheless, four mice that were treated 
with 10 mg/kg of Trolox and 4 mice with the 40 mg/kg of Trolox died. None of 
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5. Discussion 
5.1. Early mitochondrial dysfunction and increased oxidative burden  
Previously, our group has detected an increased oxidative burden in adult Mecp2−/y 
hippocampal tissue (Großer et al., 2012). Therefore, the question arose whether the 
underlying dysfunction in mitochondrial metabolism is a primary or secondary cause 
in Rett syndrome. In the present thesis, the analyses of mitochondrial metabolism in  
P7-10 Mecp2-/y mice revealed that in neonatal Mecp2−/y hippocampal slices the ratio 
of FAD/NADH tissue autofluorescence was already shifted towards more oxidized 
conditions. This suggests that mitochondrial dysfunction is an early and primary 
event in Rett syndrome (Großer et al., 2012). FAD/NADH changes may be explained 
by an increased turn-over rate of oxidative phosphorylation, which would lead to an 
intensified oxidation of the two reduction equivalents. Indeed, a proton leak across 
the inner mitochondrial membrane was assumed for this Rett mouse model, and 
increased respiratory rates and O2 consumption were also detected in isolated 
mitochondria obtained from brain tissue (Kriaucionis et al., 2006; Menzfeld, 2014). 
Hence, the performed autofluorescence analyses of hippocampal slices are in line 
with those findings from isolated mouse brain mitochondria, and they clearly 
confirm a neonatal onset of mitochondrial impairment in Rett syndrome. 
 
 
5.2. Antioxidant therapy – current status  
The central nervous system, especially the brain, is one of the organs with a very 
high susceptibility to oxidative damage. Large amounts of ROS are produced, 
because of the high metabolic rates of neurons and to a lesser degree also in glial 
cells. Disruption of the cellular redox balance may have severe consequences (Uttara 
et al., 2009). In fact, free radicals or oxidative damage are widely considered to 
contribute to a various number of human neurologic diseases and 
neurodegenerative diseases such as Alzheimer’s disease or Parkinson’s disease 
(Jenner, 2003), cancer (Reuter et al., 2010), cerebral stroke (Chan, 1996; Rodrigo et 






An antioxidant is considered “any substance that delays, prevents or removes 
oxidative damage to a target molecule” (Halliwell and Gutteridge, 1995; Halliwell, 
2007). Accordingly, therapeutic approaches aiming to prevent, delay or ameliorate 
an oxidative burden by free radical scavengers seem to be a potential and promising 
approach.  
 
Melatonin treatment for example reduced the lesion size in a rat focal brain 
ischemia study (Cuzzocrea et al., 2000) and suppressed epileptic discharges of 
posttraumatic epilepsy in rats (Kabuto et al., 1998). Coenzyme Q10 has been shown 
to prevent even ischemic brain lesions in rabbits (Grieb et al., 1997). The potential 
value of antioxidant treatment has not only been confirmed in animal models, 
moreover there were numerous clinical trials conducted and approved for routine 
clinical application that confirmed antioxidant treatment as an effective therapy. 
Patients with acute stroke (Nakase et al., 2011) or Alzheimer’s disease (Gutzmann 
and Hadler, 1998) that were treated with antioxidants showed an improved 
outcome. Nevertheless, one should also mention, that a number of human clinical 
studies failed although rodent studies seemed to be promising.  
 
Yet, the detailed function and effectiveness of antioxidants is not well known and 
the results of clinical studies are in part contradictory. Reasons for heterogeneous 
results may be the difficulty of optimal dose-finding and the challenge to first 
decipher in detail the individual oxidative status occurring in the different diseases 
conditions. Furthermore, an early identification of the disease and therefore, an 
early start of antioxidant treatment would be crucial to achieve clinical benefits. 
 
5.3. Antioxidant treatment in Rett syndrome  
Several studies have shown an improvement of certain clinical features of Rett 
syndrome (Chapleau et al., 2013). Especially, those pharmacotherapeutical 
treatments that aim to prevent oxidative stress by improving the cellular redox 
balance have been reported to be beneficial. In female Rett mice for example it has 
been found that alterations in the vascular and endothelial system were reversed by 
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administration of curcumin, a compound with antioxidant and anti-inflammatory 
properties (Panighini et al., 2013). Moreover, antioxidant treatment in Rett 
syndrome patients confirmed that oral supplementation with ω-3 PUFAs 
successfully improved the motor function, the non-verbal communication and the 
regularity of breathing (De Felice et al., 2012; Maffei et al., 2014).  
 
5.4. Vitamin E – The scavenger of choice  
Vitamins like vitamin A, C and E are the best studied antioxidants. They are widely 
considered to be generally safe and essential for normal development and 
maintenance. Beyond that, one more important aspect is that vitamin E deficiency 
can lead to severe neurologic dysfunctions. The primary symptoms hereby include 
cerebellar ataxia, dysarthria and mental retardation (Brigelius-Flohé and Traber, 
1999). Vitamin E, in particular, was extensively studied in several neurologic 
disorders. 
 
In transgenic amyotrophic lateral sclerosis mice, application of vitamin E led to a 
delayed onset of clinical symptoms (Gurney et al., 1996). In apoE−/− mice the 
supplementation of vitamin E significantly reduced isoprostane generation, which is 
formed in vivo from the free radical-catalyzed peroxidation of essential fatty acids 
(Pratico et al., 1998). Moreover, apoE−/− mice treated with vitamin E showed a 
significantly improved behavioral performance, which was associated with 
preservation of the dendritic structure. In addition, vitamin E-treated mice showed 
near normal levels of both lipid peroxidation and total glutathione (reduced and 
oxidized), whereas untreated apoE−/− mice had increased levels of lipid peroxidation 
and total glutathione (Veinbergs et al., 2000). Furthermore it could be shown that 
early supplementation of vitamin E reduced amyloid deposition and plaque 
formation in a mouse model of Alzheimer’s disease (Sung et al., 2004). Taken 
together, there are various successful rodent studies which confirmed the positive 
outcome of vitamin E treatment. On this basis, clinical trials were the next logical 
step in the fight against the deleterious consequences of oxidative injury in different 





In human studies, supplementation of vitamin E reduced seizure frequency in 
children with refractory epilepsy (Ogunmekan and Hwang, 1989). In a small clinical 
trial of patients with Huntington disease, treatment with vitamin E showed some 
clinical benefits (Peyser et al., 1995). Moreover, in a clinical trial of patients with 
Alzheimer’s disease, treatment with vitamin E successfully delayed some markers of 
the disease progression (Sano et al., 1997). 
 
Based on the fact, that similar symptoms occur in vitamin E deficiency (Brigelius-
Flohé and Traber, 1999) as well as low vitamin E levels were observed in Rett 
patients (Formichi et al., 1998), the main focus of this thesis was to analyze to what 
degree radical scavenging is able to rescue neuronal and mitochondrial function in 
the MeCP2-deficient mouse hippocampal network and/or to improve the physical 
constitution of Mecp2-/y mice. 
 
Hence, the radical scavenger of choice was a vitamin E derivative based on the high 
scavenging efficiency of this class of compounds, and Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) in particular was selected due to its water 
solubility. Vitamin E and its derivatives are chain-breaking antioxidants that prevent 
the propagation of free radicals in membranes and in plasma lipoproteins. Radicals 
are scavenged by vitamin E at ~1.000- times faster kinetics than by PUFAs (Buettner, 
1993; Traber and Stevens, 2011; Alberto et al., 2013). Moreover, antioxidants are 
also able to react with singlet oxygen as well as superoxide, and therefore decrease 
the cell endogenous H2O2 formation (Brigelius-Flohé and Traber, 1999; Peus et al., 
2001). In addition, vitamin E is not degraded in the scavenging process but is rather 
recycled and continuously restored by other antioxidants e.g. vitamin C, to maintain 
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5.5. Trolox treatment in vitro vs. in vivo – Synaptic plasticity 
 
5.5.1. Short -and long-term plasticity 
Acute in vitro 3–5h Trolox treatment clearly dampened neuronal hyperexcitability, 
improved synaptic plasticity, and increased the tolerance to severe hypoxia in acute 
isolated hippocampal tissue of adult and already symptomatic Mecp2-/y mice. 
Indeed, already in an earlier imaging study from our laboratory, Trolox has been 
shown to be able to decrease the elevated redox baselines in Mecp2-/y hippocampal 
slice cultures and to dampen the exaggerated redox responses to oxidant challenge 
in neonatal and hence presymptomatic mice (Großer et al., 2012).   
 
Now, it could be shown that in vitro application of Trolox improved basal synaptic 
function by decreasing selectively neuronal hyperexcitability in Mecp2-/y without 
affecting WT slices. How exactly the modulation of the neuronal network function by 
changes in cellular redox balance occurs is not predictable, especially in regard to 
the various number of ion-channels and transmitter receptors that are modulated to 
different degrees and even respond oppositely to redox modulation. For example 
oxidant challenge blocks NMDA and GABAA receptors (Aizenman et al., 1989; Sah et 
al., 2002) but activates voltage-gated Na+-channels and ryanodine receptors 
(Hammarström and Gage, 2000; Hidalgo et al., 2004; Gerich et al., 2009). But, 
independent of its underlying mechanism, the normalization of neuronal excitability 
by Trolox in Mecp2-/y slices may be of importance in view of the seizure susceptibility 
associated with Rett syndrome. In vivo Trolox treatment, however, did not reveal 
any differences between Mecp2-/y and WT mice regarding the shape of their I/O 
curves, which indicates that basal synaptic transmission is not altered.  
 
In hippocampal slices of untreated Mecp2-/y mice, short- and long-term synaptic 
plasticity was significantly impaired compared to those obtained from WT mice. 
These findings are in line with reports of synaptic deficits in previous studies 
conducted on Mecp2 null mice (Asaka et al., 2006; Moretti et al., 2006). 





plasticity. Since cognition is severely impaired in Rett syndrome, this may be an 
important finding. Although, PPF was not primarily affected, genotypic differences 
among Mecp2-/y and WT slices were no longer present upon acute Trolox treatment.  
Moreover, STP was improved and LTP was fully restored to its normal level by the 
acute in vitro application of Trolox in Mecp2-/y slices. It seems that in particular 
postsynaptic structures were modulated by the radical scavenger treatment, as 
especially long-term plasticity was improved. LTP induction at Schaffer 
collateral/CA1 synapses is mostly NMDA receptor dependent (Bliss and Collingridge, 
1993). More oxidized conditions in Mecp2-/y hippocampus may partially lead to the 
inactivation or upregulation of the oxidation-sensitive NMDA receptors (Aizenman 
et al., 1989; Betzen et al., 2009) and therefore, contribute to the less stable LTP seen 
in Rett mouse hippocampus (Asaka et al., 2006; Moretti et al., 2006; Guy et al., 
2007). It is also possible that disturbed LTP is a consequence of an altered NMDA 
receptor expression pattern or their particular NMDA receptor subunit composition 
within synapses (Maliszewska-Cyna et al., 2010). In conclusion, the Trolox-mediated 
normalization of redox balance may have restored normal NMDA receptor function 
and therefore LTP.  
 
In vitro application of Trolox in WT slices showed no effects on basal synaptic 
function, but dampened STP and also depressed LTP. This finding may be explained 
by the strict dependence of LTP on exact cellular redox balance. It has been shown 
that a certain ROS level is necessary for signal transduction cascades during normal 
physiological processes (Serrano and Klann, 2004). How important a well-balanced 
ROS level is, has been shown by overexpression of extracellular superoxide dimutase 
3 or superoxide scavenger administration, both of which revealed impairments in 
hippocampal LTP (Klann et al., 1998; Thiels et al., 2000). One more important finding 
is, that oxidative stress is able to influence the LTP maintenance without affecting 
STP or PPF (Pellmar et al., 1991). Hence, ROS are not only involved in LTP 
impairment but contribute to normal LTP and are therefore essential for synaptic 
plasticity (Knapp and Klann, 2002; Massaad and Klann, 2011). Based on the obtained 
in vitro data, a well-balanced cellular redox equilibrium and an optimized dosage of 
redox-modulators such as radical scavengers are very important. Here, only a single 
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concentration of Trolox was applied that led to an improved LTP in Mecp2-/y slices, 
but to a partial depression in WT. Accordingly, a more sensitive titration of redox 
conditions may be required to ensure that LTP improves in Mecp2-/y slices without 
dampening synaptic plasticity in WT.  
 
In the present study, the genotypic differences between Mecp2-/y and WT mice were 
evident in uninjected mice but became less pronounced in chronically treated mice 
which received PBS only or the high dose of Trolox. Interestingly, by comparing data 
from slices of untreated WT and PBS injected WT mice, the STP and LTP in slices 
from PBS injected mice are significantly lower (STP 238.2 ± 62.1% vs. 175.5 ± 42.3%; 
LTP 179.3 ± 31% vs. 156.7 ± 41.6%; n= 9-15). This might be explained by previous 
findings from in vitro and in vivo electrophysiological studies that indicate stress and 
stress hormones as one potential reason for impaired LTP in the hippocampus (Kim 
and Yoon, 1998; Kim and Diamond, 2002). Hence, chronic i.p. injections could 
certainly be considered as a chronic stressor (Ryabinin et al., 1999) and therefore, 
may lead to stress hormone release and thus impair the LTP in slices of injected WT 
mice. In slices of Mecp2-/y mice, LTP is already impaired to a degree that it might not 
be further disturbed by stress hormones. This could explain the absence of 
genotypic differences in injected mice. Another explanation could be that bidaily 
handling of mice had a positive effect on synaptic plasticity of Mecp2-/y mice, as it 
has been reported in several “enriched environment” studies (van Praag et al., 1999; 
Rampon et al., 2000).  
 
Nevertheless, also in vivo Trolox treatment revealed promising results on synaptic 
long-term plasticity. Low dose Trolox treated Mecp2-/y mice showed a significantly 
improved STP as compared to the respective WT group and the other Mecp2-/y 
groups. In contrast to the clear effects of the low dose Trolox treatment on 
hippocampal synaptic plasticity the chronic high dose in vivo treatment by repeated 
injections of Trolox did not change or improve synaptic plasticity in slices obtained 
from Mecp2-/y or WT mice, which may result from a probably too high concentration 






5.5.2. Hypoxia induced spreading depression 
Acute in vitro Trolox application abolished the increased susceptibility of Mecp2-/y 
hippocampus to O2 withdrawal i.e., Trolox reverted in Mecp2
-/y slices the onset of 
HSD to conditions seen in WT slices, whereas HSD in WT slices was not altered by 
Trolox. Also here, another protective effect that was mediated by Trolox occurred 
only in Mecp2-/y slices. It is known that treatments decreasing neuronal excitability 
postpone the onset of spreading depression while increased excitability favors its 
occurrence (Somjen, 2001). Following from this, the improvement of HSD in  
Mecp2-/y slices by Trolox may be a result of the selective dampening of neuronal 
excitability. Moreover, increased ROS levels (Grinberg et al., 2012), changes in thiol 
redox balance (Hepp et al., 2005; Hepp and Müller, 2008) and mitochondrial 
inhibition (Gerich et al., 2006) critically modulate the induction threshold of 
spreading depression. These results lead to the suggestion that a stabilized redox 
balance or an improved mitochondrial anoxia tolerance may be partly responsible 
for the postponement of HSD, seen in in vitro Trolox-treated Mecp2-/y slices. 
 
The PBS control group, in in vivo Trolox-treated mice, did not show differences in 
hypoxia susceptibility among genotypes, but the treatment with the low dose of 
Trolox decreased the hypoxia susceptibility in Mecp2-/y slices significantly as 
compared to the respective treated WT. Interestingly, this has not been seen with 
the high dose of Trolox, which may again point out to the importance of proper 
antioxidant dosing. In view of the highly irregular breathing and the associated 
intermittent systemic hypoxia in Rett syndrome (Julu et al., 2001; Stettner et al., 
2008; Katz et al., 2009), the Trolox-mediated increase in hypoxia tolerance is clearly 
of potential merit, as it may prevent additional complications especially in anoxia 
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5.6. Mitochondria are unaffected by Trolox treatment 
Mitochondria are the primary cellular source of ROS (Boveris and Chance, 1973; 
Adam-Vizi, 2005) and mitochondrial alterations in Rett syndrome underlie the 
increased oxidative burden and altered cellular redox homeostasis (Großer et al., 
2012). However, mitochondria are also potential targets for oxidative damage 
themselves, and may respond with morphological and functional changes including 
altered intracellular trafficking (Petronilli et al., 1994; Gerich et al., 2009; Qi et al., 
2011; Lenaz and Genova, 2012).  
 
Therefore, it was also assessed whether Trolox may modulate mitochondrial 
function directly. However, a noticeable improvement of mitochondrial function was 
not observed. The genotypic baseline differences in FAD/NADH ratio, a measure for 
the metabolic activity of mitochondria, were not significantly affected by acute 
Trolox administration. During mitochondrial challenging with 1 mM CN-, only a small 
effect on the anoxic drop in FAD/NADH ratio was mediated by Trolox, which may 
suggest a slightly increased anoxia tolerance of mitochondrial respiration. Yet, no 
corresponding effects on Δψm were observed. Furthermore, slightly increased Rh123 
responses in both WT and Mecp2-/y slices during FCCP uncoupling, or the tendency 
of increased Rh123 responses to high CN- concentrations in Mecp2-/y slices may 
suggest some improvement of Δψm. 
 
These findings revealed that the protective effects of vitamin E reported for rat liver 
mitochondria, i.e., partial normalization of the increased state 3 and state 4 
respiration upon acute lipid peroxidation (Ham and Liebler, 1997), do not necessarily 
apply to the disturbed hippocampal mitochondria of Rett mice. Nevertheless, 
regarding the obtained data it can at least be confirmed that Trolox treatment did 
not lead to any negative side effects on mitochondrial function in WT and especially 
in Mecp2-/y slices.  
 
In contrast, after chronic i.p. administration of Trolox, any impairment in 





Surprisingly, also the PBS control group did not show any differences between 
Mecp2-/y and WT mice. It should be noted here that the FAD/NADH recordings for 
acute and chronic treatment were performed on two different setups with different 
light sources. This may explain the differences seen in the FAD/NADH baseline 
conditions. Also stress, resulting from bidaily injection, might have had an impact on 
mitochondrial metabolism, which could mask the genotypic differences, since it has 
been shown that most of the primary mediators of stress responses exert numerous 
effects on mitochondrial metabolism and ROS generation and may even induce 
apoptosis (Manoli et al., 2007).  
 
5.7. No in vitro effect of Trolox on seizure susceptibility 
Even though acute Trolox treatment reduced neuronal excitability in Mecp2-/y slices, 
an obvious reduction in seizure susceptibility was not observed. Nevertheless, the 
onset of SLEs tended to be postponed only in WT slices and the duration of the 
individual SLEs tended to be decreased by Trolox in both WT and Mecp2-/y slices. 
Although a decrease in the SLE duration was observed in both genotypes, it may be 
of some profit by dampening the severity of seizures once such abnormal discharges 
are triggered. But it should be also considered, however, that the K+-channel 
inhibitor 4-AP is rather a strong convulsive stimulus. Nevertheless, a pronounced 
seizure susceptibility is associated with Rett syndrome, and it even constitutes a 
potential cause for sudden death (Hagberg et al., 1983; Steffenburg et al., 2001). 
Therefore, it is an important finding that the Trolox-mediated normalization of 
synaptic plasticity in Mecp2-/y hippocampus is not associated with negative side 
effects such as increased neuronal excitability and/or increased seizure 
susceptibility. The seizure susceptibility has not been assessed in slices of the 
chronically injected mice because of the following reasons: The results of untreated 
mice did not reveal a higher epileptic activity in slices of Mecp2-/y mice as compared 
to WT and therefore, there was no need to test this in slices from injected mice. Also 
I/O curves of injected mice did not differ among genotypes and no obvious signs of 
hyperexcitability were seen. Moreover, due to the restricted number of mice that 
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were allowed to use for the in vivo study, the main focus was to screen for 
improvements in those experiments that showed already promising results in vitro.  
 
5.8. In vivo Trolox treatment - influences on systemic parameters 
Systemic treatment of mice with Trolox up to ~P50 did change neither the 
progression of Rett-symptoms nor the systemic parameters, such as the body weight 
or the hematocrit. Mecp2-/y mice were not distinguishable from their WT littermates 
until around P20. Around this time mice were separated from their foster mothers 
and started to develop significant differences in their body weight, which is in line 
with earlier studies on untreated Rett mice (Guy et al., 2001).  
 
The hematocrit of Mecp2-/y mice was in all treatment groups elevated as compared 
to WT mice. This can be explained by the fact that severe, intermittent hypoxia 
arising from unstable breathing increases the hematocrit as an adaptation to chronic 
oxygen shortage. Such adaptation to hypoxia has been consistently reported to 
increase the hematocrit and is one of the mechanisms contributing to the increased 
tolerance to hypoxia (Burton et al., 1969). Also in this aspect, treatment with Trolox 
did not mediate any improvement. 
 
Analyses of the blood glucose content revealed a lower level in Mecp2-/y mice in 
comparison to WT. Nevertheless, the blood glucose level of the low dose Trolox 
treated group could be restored to WT level. Previously, it has been shown that, 
indeed, Mecp2 null mice are associated with metabolic abnormalities including 
hyperinsulinemia (Pitcher et al., 2013). Such high levels of insulin could well lead to a 
depression of blood glucose content. As neurons rely on the energy derived from 










5.9. In vivo treatment – breathing disturbances 
One of the most prominent symptoms in Rett syndrome is a remarkable breathing 
abnormality. Most Rett patients and Mecp2 mutant mouse models suffer from 
breath holding, aerophagia, hyperventilation and recurrent apneas (Julu et al., 2001; 
Stettner et al., 2008; Katz et al., 2009; De Felice et al., 2010; Ramirez et al., 2013). 
 
Each episode of irregular breathing evokes a significant drop in arterial oxygen 
saturation, which is rapidly restored only after normal ventilation resumes. Thus, 
these repetitive changes of oxygen saturation may cause damage to the sensitive 
neuronal tissue (Love, 1999). Though, different mechanisms are involved, such 
damage is mainly linked to the formation of ROS. ROS are highly reactive molecules 
and are considered to play an important role in the development of cardiovascular 
diseases (Sugamura and Keaney, 2011) and moreover to mediate neuronal damage 
(Uttara et al., 2009). 
 
In Rett patients, untreated episodes of hypoxia may lead to cumulative redox 
challenge and therefore, play a role in the onset and/or progression of 
cardiovascular and neuronal complications. This led to the question, if antioxidant 
treatment could improve the breathing of Mecp2-/y mice, by opposing and/or 
dampening the oxidative challenge. In line with other studies, Mecp2-/y mice 
displayed a highly irregular breathing pattern (Viemari et al., 2005; Stettner et al., 
2008; Katz et al., 2009). Treatment with Trolox did not reveal any beneficial outcome 
on the regularity of breathing nor the frequency of observed apneas, but also did 
not deteriorate the breathing further. The number and the intensity of the severe 
apneas affecting Mecp2-/y mice were not changed after chronic Trolox treatment, 
but it has also to be mentioned that there is a great variability between individual 
Mecp2-/y mice. Some Rett mice displayed milder breathing disturbances with only 1 
apnea over the evaluated time interval whereas others showed 35 apneas. Thus, the 
outcome of the Trolox treatment could also be masked by mice with a very 
pronounced respiratory phenotype. 
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5.10. In vivo Trolox treatment and its outcome on motor and 
exploration behavior 
Another clinical feature of Rett syndrome is that Rett girls lose already acquired 
motor skills such as purposeful hand use and walking. Analysis of the impact of 
MeCP2 deficiency on motor and behavior skills has previously been conducted on 
Mecp2308/y mice, which display an obvious milder phenotype (Shahbazian et al., 
2002; Moretti et al., 2005).  
 
In the present study, Mecp2-/y mice showed a clear impairment in motor 
performance and motor learning with significant differences in the time spent on 
the rotarod among all Mecp2-/y treatment groups compared to the WT groups. 
These findings clearly show that antioxidant treatment was not able to restore or 
improve motor function. The poor performance on the rotarod can be most likely 
excluded to be a result of muscle weakness, as almost all Mecp2-/y mice were still 
able to climb around in their cages. Also, normal muscle strength has been shown by 
the wire suspension test, in which mice were forced to grasp a wire and hang from it 
on their forepaws. The ability of Mecp2-/y mice to grasp the wire was comparable to 
WT mice (Santos et al., 2007). However, intact motor coordination is necessary for a 
good performance in the rotarod test. The limb coordination deficiency that is 
indicated by the hind limb clasping is apparently present in Mecp2-/y mice. Regarding 
therefore the obtained data in this thesis, it seems that the poor performance on 
the rotarod is due to severely affected hind limbs.  
 
Rett patients as well as Mecp2-/y mice show a decreased activity and hypoactivity 
(Guy et al., 2001). Also in the present study, Mecp2-/y mice traveled significantly 
shorter distances, which in the open field test became evident as a decline in their 
mean velocity and as prolonged resting times. Distinct differences in the times spent 
in the zones: periphery, center and corner could not be observed, although the low 
dose Trolox treated Mecp2-/y group tended to spend more time in the periphery and 
corner when compared to the respective WT. Taken together, Mecp2-/y mice showed 





mice. Furthermore, one could suggest that even though Mecp2-/y mice seem to 
habituate to the open field environment to some extent, based on their decreased 
locomotor activity over time they may have maintained a higher level of overall 
anxiety than WT mice (Paylor et al., 1998).  
 
5.11. Résumé of systemic Trolox treatment 
In contrast to the clear effects of acute Trolox application on hippocampal synaptic 
transmission in vitro, the chronic treatment of mice with Trolox did not change the 
progression of characteristic Rett syndrome symptoms. This leads to the suggestion 
that Trolox may not hold promise in treating the full range of symptoms of Rett 
mice. Yet, one has to bear in mind that Mecp2-/y male mice are very severely 
affected. Therefore, it remains to be tested whether Trolox would be more valuable 
in heterozygous females, which exhibit a much milder and more stable phenotype. 
Furthermore, assessment of the full pharmacotherapeutic potential of Trolox to 
improve the phenotype of Rett mice in vivo requires adequate specific outcome 
assays, especially defined tests for the blood brain barrier permeability of this 
compound. Also, the potential influence on frequent animal handling and drug 
injections have to be taken into account. In particular, injections can lead to a high 
stress response and may change or mask the outcome of possible positive results.  
 
In the present study, Trolox was administered via i.p. injections. It is possible that 
other administration routes would be more effective and potentially could improve 
or rescue some of the symptoms. Also, alternatives such as the use of minipumps or 
oral feeding should be considered, though injections are the only way to ensure the 
animal, indeed, received the desired concentration of the drug. The use of 
minipumps underlies certain limitations as they are not feasible for mice at early 
postnatal stages. Oral feeding could also just start ~P20, otherwise the mother 
would have to be fed, so that the administered drug could be forwarded via the 
mother’s milk to the suckling pups. Yet in that case, a tight control of the exact drug 
concentration taken up by the pups would be almost impossible. 
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5.12. Issues in therapeutic treatment strategies  
Although, there is strong evidence that early mitochondrial dysfunction and early 
oxidative stress occur in Mecp2-/y mice, further evaluation whether oxidative stress 
is really the primary cause of the disease, needs to be performed. It is important to 
know if oxidative damage is a direct initial critical factor or just a byproduct of other 
disturbed upstream pathways. Thus, if oxidative injury is only a consequence of 
overall failing cellular cascades in Rett syndrome, it may be too late for an 
antioxidant treatment. In addition, oxidative stress may be only one of different 
processes in disease development and progression. The mechanistic insights into 
other diseases showed that in ischemic cell death oxidative damage goes along with 
many other deleterious processes such as inflammation and excitotoxicity. Hence, to 
achieve successful therapy, compounds which act on multiple targets have to be 
developed.  
 
Even though all Mecp2-/y mice have the same genetic background, there is a high 
variance in the phenotype. Some mice show an almost normal body weight, do not 
display obvious motor problems and appear quite healthy as compared to other 
Mecp2-/y mice. Differences in the phenotype are also very prominent in Rett girls. It 
may be that a poor outcome of the supplementation of antioxidants is due to the 
fact that mice and/or patients do not equally benefit from an antioxidant treatment. 
The degree and true course of oxidative stress might also vary between individuals. 
Because of this heterozygous population, the outcome of antioxidant treatment may 
differ considerably among the treated individuals. Some may clearly benefit from 
such treatment whereas others might not. The resulting variability might than be 
interpreted as a less satisfactory result. Defined biochemical analysis would be 
required, to ensure treatment of only those individuals with a strong redox 
imbalance. Hence, patients without clear biochemical evidence of increased 
oxidative stress could be excluded from clinical trials.  
 
In summary, careful recruitment criteria have to be established to determine who is 





trial, it has to be certain that the antioxidant is, indeed, able to reduce oxidative 
injury in vivo. Therefore, one has to consider different points (Firuzi et al., 2011). 
 
(1) The bioavailability should be high enough, to ensure that reliable amounts of the 
drug can reach the target. Indeed, when a medication is administered, its 
bioavailability generally decreases or may vary from patient to patient. 
Bioavailability is one of the crucial tools in pharmacokinetics, and must be 
considered when calculating the exact dosage.  
 
(2) The time and duration of supplementation plays an important role for the 
success of a clinical trial. Most patients are likely to suffer already for a long time 
from the consequences of oxidative stress. Clearly, in most cases, a short-time 
antioxidant therapy cannot compensate or reverse for those long-term existing 
effects and damages. In addition, in most cases the therapy starts too late in the 
disease progression to show beneficial effects. Moreover, the optimal duration of 
treatment has to match the very type of the disease. While, long-term treatment is 
needed for cancer prevention, long-term therapy may not always be feasible, as 
long-term treatment could lower ROS formation to a level that may be detrimental 
for cells as ROS are essential signaling molecules (Finkel, 2011). 
 
(3) The use of insufficient doses of vitamin E, could be another explanation for the 
lack of obvious positive results. Therefore, a dose-ranging study in which different 
doses of a compound are tested against each other to clarify which dose works best, 
should be run first. In addition, it has to be excluded that the reaction products, 
arising from the interaction of antioxidant and ROS, do not lead to potentially 
harmful downstream products. 
 
(4) In some diseases it might be not easy to successfully overcome oxidative stress. If 
the balance in the cell is already intensely disturbed, the amount of antioxidants that 
would be necessary to equilibrate the redox imbalance may be too high and the 
required concentrations could be even toxic.  
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(5) Target specificity is another point that has to be considered. The administration 
of antioxidants mediates systemic effects but oxidative damage may be restricted to 
one specific organ or tissue.  
 
(6) In most studies, only a single antioxidant compound is used, but to achieve the 
optimal outcome, one should consider a combination of different antioxidants, 
especially as vitamins work synergistically. It has been shown that vitamin E is 
particularly more efficient when administered together with vitamin C (Robinson et 
al., 2006).  
 
(7) One of the biggest challenges is the limited knowledge of the blood brain barrier 
permeability for antioxidants when applied systemically. Therefore, for any novel 
planned antioxidant treatment it should be mandatory that this compound is well 
able to cross the blood brain barrier after systemic administration. 
 
In summary, it is challenging to identify “the” best working antioxidant, but it should 
be desirable to develop new strategies by combining the existing knowledge of the 
properties of antioxidant compounds on novel drug approaches for Rett syndrome 
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6. Conclusions and future perspectives 
In conclusion, the obtained data suggest that oxidative stress plays a key role in the 
mechanisms of some of the characteristic neurological features in Rett syndrome. 
The present thesis confirmed a reduction in neuronal hyperexcitability, 
improvement of synaptic short-term plasticity, and restoration of synaptic long-term 
potentiation in Mecp2-/y mice following the incubation of acute hippocampal slices 
with the free radical scavenger Trolox (Janc and Müller, 2014). This concept was also 
supported by a previous pilot study in Rett patients at an early stage of the disease 
using ω-3 PUFAs (De Felice et al., 2012).  
 
Like the in vitro promising results, in vivo Trolox treatment also turned out to be an 
effective pharmacological therapy in blood glucose level, hypoxia tolerance and 
short-term plasticity. Based on the these positive findings upon treatment, the low 
dose treatment of Trolox should be preferred and optimized for further experiments 
that may either slow down the disease progression or reverse the typical symptoms 
in male Rett mice. 
 
Further experiments regarding the survival of in vivo Trolox-treated mice have to be 
performed. The expected lifespan of Mecp2-/y mice is about 50-60 days. To evaluate 
whether Trolox treatment leads to a prolongation of the lifespan, mice shall be 
injected over a longer period of time (~100 days) or as long as they survive. 
 
Moreover, for future studies, and especially for long-term treatment, other 
application routes of Trolox such as self feeding or forced oral supplementation have 
to be considered as frequent i.p. injections seem to have a strong impact on the 
outcome of antioxidant treatment. Therefore, the design of the study has to be 
optimized.  
 
To test whether hippocampus-dependent learning may improve by Trolox 
treatment, the Y-maze test has been already started, but so far only a small number 
of mice was tested to draw a conclusion.  




Although, MeCP2 expression in heterozygous female mice leads to inconsistent 
symptoms and highly variable phenotypes, to get a full picture of the Trolox therapy, 
also female mice have to be included in the scavenger treatment. Possibly, it is only 
in those less severely affected female mice, that some degree of improvement could 
be achieved by antioxidant treatment.  
 
After all, redox imbalance is only one potential reason of the several symptoms 
associated with Rett syndrome and it may potentially challenge neuronal function of 
MeCP2-deficient neuronal networks. 
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